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PREFACE	
The experimental work, on which this PhD thesis is based, has been performed during the years 
2010-2012 at the Technical University of Denmark, National Veterinary Institute (DTU-Vet) - 
Lindholm. The project was funded by the European Community’s Seventh Framework (FP/2007-
2013) CSFV_goDIVA project and by the Technical University of Denmark.  
The EU network of excellence “EPIZONE” (Contract no Food CT-2006-016236) provided funding 
for a “short term mission” with training at Anses, Ploufragan-Plouzane laboratory, Swine Virology 
and Immunology Unit, BP53, 22440 Ploufragan, France.  
As a new area of research for me, the opportunity to be a part of a big international consortium and 
to be involved in all aspects of the development of a new product from testing to registration was 
extremely valuable. This project enabled me to learn a lot about development and production of 
vaccines and to get to know a large number of people working with Classical Swine Fever from 
across the world.  
I am grateful to all of those who in different ways have helped me during this process.  
In particular I would like to thank my supervisor Åse Uttenthal for always finding the time to listen 
and be helpful. She was always there for me to read and comment on my papers, discuss new ideas 
and laboratory results. Her enthusiasm and devotion to her work were very inspiring and her sense 
of humor made each work day easier. 
I would like to thank Jens Nielsen for helping me to design the animal experiments, and with the 
clinical work and the autopsies. I appreciate the timely and helpful comments he provided for my 
papers.   
I am grateful to Patricia Renson and Marie-Frederique Le Potier (Anses, France) for inviting me to 
their laboratory and for taking good care of me during my visit. Patricia contributed considerably to 
the immunological evaluation of some of the samples and the interpretation of the results. She was 
very kind and patient in teaching me various techniques and in showing me many beautiful places 
in Brittany. I had a great time at Saint–Brieuc. 
The laboratory technicians at Lindholm Grith, Nethe, Frank, Pernille, Eva, Hanna, Katrine, Dorota 
and Lone gave me invaluable assistance.  
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I truly appreciate the animal keepers Marion, Henrik, Janni, Ove, Rikke and Heidi for their efforts 
during the four and a half months animal experiment, for the nights and weekends spent on the 
island.   
I would like to thank Peter Risager for making the long drive enjoyable and for always being 
friendly and helpful. 
I truly appreciate the support of my former colleagues from the Danish Medicine Agency when I 
was contemplating whether to start this project. 
I am grateful to all of my friends Juji, Dani, Krasi, Iveta and Soraya for always being there for me. 
My father is thanked for always supporting me and being interested in my education. 
Most of all I would like to thank my partner, Martin, for agreeing to join me on this amazing 
journey.  I am so grateful for your support and trust in me and for taking care of our son and the 
housekeeping during my absences.  I am grateful for my son Nikolaj for being such a wonderful 
child, for helping me keep things in perspective, and for always making me smile.  
 
 
 
 
Desislava Rangelova, Lindholm, January 2013 
 
  
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
6 
 
ABBREVIATIONS	
 
APC- antigen presenting cell 
APP- acute phase protein 
B-cell- bone marrow- derived lymphocyte 
BDV- Border disease virus 
BVDV- Bovine viral diarrhea virus 
CD4 - cluster of differentiation 4 
CD8 - cluster of differentiation 8 
CRP- C-reactive protein 
CSF- Classical swine fever   
CSFV- Classical swine fever virus  
CS- clinical scores 
C-strain- Chinese strain 
CTL- cytotoxic T lymphocytes 
Ct – cycle threshold 
cDNA- complimentary DNA 
DIVA- differentiating infection in vaccinated animals 
DNA- deoxyribonucleic acid 
DPC-days post challenge 
DPV- days post vaccination 
ELISA- enzyme-linked immunosorbent assay 
EU- European Union 
GMO- genetically modified organism 
GPE- - quinea-pig exaltation-negative strain 
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IFN- interferon 
Ig- immunoglobulin  
IL- interleukin 
MDA- maternal derived antibdies 
NPLA – neutralization peroxidase-linked assay 
NTR- non-translated region  
OIE- Office International des epizooties 
ORF- open reading frame  
PBS - phosphate buffered saline 
PK-15 – pigs kidneys cells  
RNA- ribonucleic acid 
RT-qPCR - real time reverse transcription polymerase chain reaction 
SE – standard error 
SD – standard deviation 
T cell - thymus-derived lymphocytes  
TCID50 - tissue culture infective dose 50% 
Th- T helper cells 
TNF-α – tumor necrosis factor alpha 
VI- virus isolation 
VNT- virus neutralization test 
WBC – white blood cells 
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SUMMARY	(English)	
General	purpose	and	objectives		
Classical swine fever (CSF) is a highly contagious disease that causes huge economical losses and 
animal welfare concerns worldwide. Generally, vaccination is an effective and safe method to 
control the disease. Following vaccination the pig’s immune system develops antibodies that are 
significant part of the protection. However, vaccination with the only live attenuated vaccines 
existing on the market that contain a whole CSF virus (CSFV) with reduced infectivity, leads to 
production of an antibody response that does not differ from the antibody response developed after 
infection. Thus, implementation of these vaccines in case of outbreak will not give the possibility to 
differentiate infection in vaccinated animals (DIVA). For countries like Denmark, which are heavily 
dependent upon export of pigs and pig products the use of these traditional vaccines, will hamper 
the ability to proof a disease free status by serosurveillance, as all vaccinated piglets will be 
seropositive.   
This PhD-project is a part of an EU project (CSFV_goDIVA grant no 227003) that has been funded 
by the European Commission with a main goal to develop and test to a level of registration a new 
DIVA vaccine candidate. The vaccine candidate “CP7E2alf” is intended for either intramuscular 
vaccination of domestic pig or for bait vaccination of wild boar. In this thesis as part of the clinical 
testing of the injection vaccine the efficacy of “CP7E2alf” was evaluated in young piglets that were 
positive for maternally derived antibodies (MDA). These antibodies were obtained with colostrum 
from their mothers vaccinated with traditional live attenuated vaccine C-strain (Riems). The 
promising results concerning the safety and the efficacy of the candidate DIVA vaccine showed 
new opportunities for control of a possible CSF outbreak that will have reduced impact on the 
export.  
Structure	of	the	thesis	
The thesis comprises three chapters: 
Chapter 1 is an introductory review of the literature giving a brief presentation of CSF including the 
current knowledge concerning CSFV and the disease. Strategies for prevention and control of CSF 
are presented, such as the use of vaccines and the DIVA vaccines concept. A description of the 
interplay between vaccines and maternal immunity in the young piglet is included and the 
characteristics of the new marker vaccine candidate “CP7_E2alf” are presented in this part. The 
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PhD work is based on a large vaccination experiment which is described in the 3 manuscripts (see 
chapter 2). A small pilot study that involved 12 pigs vaccinated intramuscularly with one dose of C-
strain vaccine was conducted at the beginning of the project. The study aimed to evaluate the 
humoral immune response after C-strain vaccination. The data were presented as part of a poster 1 
and a graph is included in Chapter 1.  
Chapter 2 describes the results generated during the PhD project, presented in three manuscripts. 
Manuscript 1, “Efficacy of marker vaccine candidate CP7_E2alf in piglets with maternally derived 
C-strain antibodies” by D. Rangelova, J. Nielsen, B. Strandbygaard, F. Koenen, S. Blome, Å. 
Uttenthal. Vaccine (30), 6376-6381. 
This published paper describes the clinical evaluation of intramuscular vaccination with the DIVA 
candidate “CP7_E2alf” of piglets with C-strain MDA at 5 or 8 weeks of age. The vaccinated piglets 
together with their mock-vaccinated controls were challenged with highly virulent CSF strain 
“Koslov” two weeks post vaccination. The piglets were clinically observed for two weeks. 
“CP7_E2alf” proved to be effective in both age groups as it prevented mortality, morbidity and 
pathological lesions. The paper discusses as well the attenuation of the challenge virus in the 
control-mock vaccinated piglets and the relevancy of the clinical parameters followed. This animal 
experiment was the base for the research conducted in this thesis. The samples collected during the 
experiment provided material for further evaluation of the “CP7_E2alf” vaccine characteristics.  
Manuscript 2, “DIVA potential of marker vaccine candidate CP7_E2alf in face of C-strain maternal 
immunity” by D. Rangelova, Å. Uttenthal. Vaccine - submitted. 
This submitted manuscript evaluates the DIVA potential of the marker vaccine candidate in 
presence of C-strain MDA. The possibility for transmission with colostrums and detection of CSF 
E2 and Erns specific antibodies was investigated. It was revealed that the candidate marker vaccine 
could be implemented as a DIVA vaccine in populations previously vaccinated with live attenuated 
vaccines as early as 5 weeks of age. No presence of specific discriminatory maternal antibodies and 
                                                            
1 A Comparative Study of CSFV Antibody Levels in Pigs Vaccinated with the Chimeric Vaccine 
CP7_E2GIF or a C-Strain Vaccine.  von Rosen, T; Rangelova, D.; Rasmussen, TB; Nielsen, J; Uttenthal, 
Å. Poster EPIZONE meeting Arnhem, Holland 2011  
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no interference with the DIVA concept were detected in older than 4 weeks of age piglets. Virus 
neutralization studies supported that E2 was transferred very efficiently from the sows to the 
piglets; shortly after uptake of colostrums the piglets had reached the same level of E2 antibodies as 
their mothers. 
Manuscript 3, “Evaluation of immune modulation in sows vaccinated with C-strain and in their 
piglets vaccinated with new candidate marker vaccine CP7_E2alf” D. Rangelova. J. Nielsen, P. 
Renson, M.F. Le Potier, Å. Uttenthal. 
This manuscript is prepared for journal of Veterinary Research. The manuscript evaluates the 
predominant activation of innate, humoral and cellular immunity in piglets positive for C-strain 
MDA that were vaccinated with “CP7_E2alf”. Both IgG1 and IgG2 were transferred with colostrum 
to the piglets. The induction of IgG1 and IgG2 isotype specific antibodies was evaluated both in the 
mothers vaccinated intramuscularly with C-strain vaccine and in the piglets vaccinated with 
“CP7_E2alf”. Additionally, IL-4 and IFN-γ cytokines that are related to IgG1 and IgG2 isotype 
specific antibodies, respectively, were evaluated in the piglets post infection. The blood kinetics of 
C-reactive protein as a component of the innate immune response was studied post challenge. It 
seems that the two vaccines exploit different mechanisms of the immune system as following 
intramuscular vaccination with C-strain there was a predominance induction of IgG2 and oppositely 
post “CP7_E2alf” vaccination mostly IgG1 was detected. 
Chapter 3 includes general discussion of the obtained results, overall conclusions and future 
perspectives for continued research. In general it is concluded that with an optimal DIVA diagnostic 
tool, “CP7_E2alf” will be a very valuable additional control measure that definitely will be 
considered to implement in Denmark in case of outbreak. 
 
 
 
 
 
 
 
 
 
 
 
11 
 
DANSK	SAMMENDRAG	
 
Generelt	formål	og	hensigt 
Klassisk svinepest (CSF) er en meget smitsom sygdom, der har enorm betydning for økonomi og 
dyrevelfærd i svineproduktionen i hele verden. Generelt er vaccination en effektiv og sikker metode 
til at bekæmpe sygdommen. Efter vaccination udvikler grisens immunsystem antistoffer, disse er en 
væsentlig del af beskyttelsen. Imidlertid er den eneste kommercielle vaccine en levende afsvækket 
vaccine, der indeholder hel klassisk svinepestvirus (CSFV). Vaccination med denne vaccine fører til 
et antistof respons, som ikke kan skelnes fra antistofreaktion efter infektion. Anvendelse af disse 
vacciner, i tilfælde af udbrud, giver ikke mulighed for at påvise infektion blandt vaccinerede dyr 
(DIVA). For lande som Danmark, der har stor eksport af svin og svineprodukter, vil brugen af disse 
traditionelle vacciner, hindre muligheden for at påvise sygdomsfri status ved serologisk 
overvågning, idet alle vaccinerede grise vil være antistof positive. 
Dette ph.d.-projekt er en del af CSFV_goDIVA (bevilling nr. 227003), der er finansieret af EU FP7 
med det hovedmål at udvikle og afprøve en ny DIVA vaccine kandidat og føre den frem til 
registrering. Vaccine kandidaten "CP7E2alf" er beregnet til intramuskulær vaccination af 
produktions svin eller til oral ”bait” vaccination af vildsvin. Som en del af den kliniske afprøvning 
af injektions vaccinen er effekten af "CP7E2alf" blev evalueret hos smågrise, der var positive for 
maternelle antistoffer, studiet danner basis for denne afhandling. Pattegrisene fik antistoffer med 
råmælk fra deres mødre vaccineret med traditionelle levende svækket vaccine C-stamme (Riems). 
De lovende resultater vedrørende sikkerhed og effekt af kandidaten DIVA vaccinen anviser nye 
muligheder for kontrol af et eventuel CSF udbrud. Brug af DIVA vaccine vil have kortere 
indflydelse på eksporten end brug af levende vaccine. 
 
Struktur	af	afhandlingen 
Afhandlingen består af tre kapitler: 
Kapitel 1 gennemgår litteraturen og giver en kort præsentation af CSF, herunder den aktuelle viden 
om CSFV og sygdommen. Strategier for forebyggelse og kontrol af CSF præsenteres, såsom brug 
af vacciner og DIVA vaccine konceptet. En beskrivelse af samspillet mellem vacciner og maternel 
immunitet i den nyfødte gris er inkluderet, og de særlige kendetegn ved den nye markørvaccine 
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kandidat "CP7_E2alf" præsenteres i denne del. Ph.d. arbejde er baseret på et stor vaccinations 
eksperiment, som er beskrevet i de 3 manuskripter (se kapitel 2). Et mindre pilotstudie, der 
involverede 12 fravænnings grise, vaccinerede intramuskulært med én dosis C-strain vaccine 
gennemførtes i starten af phd projektet. Forsøgets formål var at evaluere det humorale 
immunrespons efter C-strain vaccination. Data blev præsenteret som en del af en poster2 og en graf 
er inkluderet i kapitel 1. 
Kapitel 2 beskriver de resultater, der er genereret i løbet af ph.d.-projektet, præsenteret i tre 
manuskripter. Manuscript 1, "Effekten af markørvaccine kandidat CP7_E2alf i smågrise med 
maternelle C-stamme antistoffer" af D. Rangelova, J. Nielsen, B. Strandbygaard, F. Koenen, S. 
Blome, Å. Uttenthal. Vaccine (30), 6376-6381. Denne publikation beskriver den kliniske vurdering 
af intramuskulær vaccination med DIVA kandidat "CP7_E2alf" i 5 eller 8 ugers smågrise med 
maternel immunitet fra C-stammen. De vaccinerede smågrise blev, sammen med de placebo-
vaccinerede kontrol grise, podet med den høj-virulente CSF-stamme "Koslov" to uger efter 
vaccination. Grisene blev fulgt klinisk i to uger. "CP7_E2alf" viste sig at være effektiv i både 5 og 8 
ugers grise, idet den forhindrede dødelighed, sygdom og patologiske forandringer. I publikationen 
diskuteres endvidere reduktionen af dødeligheden efter virusbelasting i kontrol-vaccinerede grise og 
relevansen af de kliniske parametre, der er analyseret. Dette dyreforsøg danner grundlaget for den 
øvrige forskning i denne afhandling. Prøver fra forsøget analyseres og anvendes til nærmere 
vurdering af vaccine egenskaberne for "CP7_E2alf". 
Manuscript 2, "DIVA potentiale af markørvaccine kandidat CP7_E2alf under indflydelse af 
maternel immunitet fra C-stammen" af D. Rangelova, Å. Uttenthal. Indsendt til Vaccine. 
Dette indsendte manuskript evaluerer DIVA potentialet af markør vaccinen i smågrise med 
maternel immunitet fra C-stamme vaccine. Både CSF E2 og Erns specifikke antistoffer kunne 
påvises i smågrisene efter optag af råmælk. Det påvistes, at kandidat markørvaccinen beholdt DIVA 
potentialet ved vaccination i populationer, der tidligere er vaccineret med levende svækkede 
vacciner. Smågrise kunne vaccineres fra 5 uger. Efter 4 uger blev der ikke påvist specifikke 
diskriminerende maternelle antistoffer i smågrisene og den maternelle immunitet gav ingen 
                                                            
2 A Comparative Study of CSFV Antibody Levels in Pigs Vaccinated with the Chimeric Vaccine 
CP7_E2GIF or a C-Strain Vaccine.  von Rosen, Tanya; Rangelova, Desislava Yordanova; Rasmussen, 
Thomas Bruun; Nielsen, Jens; Uttenthal, Åse. Poster EPIZONE møde Arnhem, Holland 2011 
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interferens med DIVA konceptet. Virusneutralisations undersøgelser underbyggede, at E2 meget 
effektivt overførtes fra søerne til pattegrisene. Kort efter optagelse af råmælk havde pattegrisene 
nået det samme niveau af E2-antistoffer som deres mødre. 
Manuscript 3, "Evaluering af immunmodulering i søer vaccineret med C-stamme og i deres 
smågrise vaccineret med ny markørvaccine CP7_E2alf" D. Rangelova. J. Nielsen, P. Renson, M.F. 
Le Potier, Å. Uttenthal. Dette manuskript er forberedt til Journal of Veterinary Research. 
Manuskriptet evaluerer den medfødte immunitet og aktiveringen af humoral og cellulær immunitet 
hos smågrise med maternel immunitet, vaccineret med "CP7_E2alf". Både IgG1 og IgG2 overførtes 
med råmælk til pattegrisene. Induktion af IgG1 og IgG2 isotype specifikke antistoffer blev påvist 
både i søerne vaccinerede intramuskulært med C-stamme vaccine og i grisene vaccinerede med 
"CP7_E2alf". Desuden blev IL-4 og IFN-γ cytokiner, der er relateret til henholdsvis IgG1 og IgG2 
isotype specifikke antistoffer, målt i grise efter virusbelastning. Kinetikken for C-reaktivt protein, 
som en komponent af den medfødte immunitet, blev undersøgt efter virusbelastning. De to vacciner 
benytter tilsyneladende to forskellige mekanismer i immunsystemet: efter intramuskulær 
vaccination med C-stammen sås overvejende induktion af IgG2, hvorimod "CP7_E2alf" 
vaccination især inducerede IgG1. 
Kapitel 3 omfatter en generel diskussion af de opnåede resultater samt overordnede konklusioner og 
fremtidige perspektiver for fortsat forskning. Generelt konkluderes det, at med en optimal DIVA 
diagnostik, vil DIVA vaccinen "CP7_E2alf" tilføje en meget værdifuld kontrol mulighed, der vil 
kunne anvendes i Danmark ved udbrud af klassisk svinepest. 
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CHAPTER 1.	
 
A background orientation for the work performed during the Ph.D. project is given in this part. This 
involves 1) a general description of Classical Swine Fever 2) a short review of the used vaccines in 
practice 3) introduction to DIVA vaccines 4) challenges of early life vaccinology 5) the new third 
generation chimeric vaccine candidate CP7_E2alf.  
General	Introduction	
	1).	Description	of	Classical	Swine	Fever	
Pestiviruses	Taxonomy	
The genus Pestivirus of the family Flaviviridae contains the four accepted species Bovine viral 
diarrhea virus (BVDV1 and 2), Classical swine fever virus (CSFV), and Border disease virus 
(BDV). Several new species have been suggested, such as the HoBi isolated from fetal calf serum 
and from cattle in Thailand and the porcine Bungowannah virus (Fig. 1) (Kirkland et al., 2007; Liu 
et al., 2009b; Ståhl et al., 2010). 
 
 
Fig.1 Phylogeny and suggested classification of pestiviruses by Maximum likelihood and Bayesian approach 
(Liu et al., 2009b). Only BVD I and II, BDV and CSFV are accepted species according to ICTV. 
 
 
 
 
 
 
16 
 
 The classification of pestiviruses is mainly based on the host species. The natural host of classical 
swine fever (CSF) is pigs, however natural BDV infections are not restricted to sheep, and 
infections of pig, cattle and reindeer have been reported (Arnal et al., 2004). BVDV could infect 
both pigs as well as ruminants.  
Classical	Swine	Fever	Virus	–	Taxonomy,	Structure,	Immunogenicity	and	Stability		
Based on genome sequencing, CSFVs were grouped into three or four subgroups: 1.1, 1.2, 1.3; 2.1, 
2.2, 2.3; 3.1, 3.2, 3.3, and 3.4. Group 1 represents mostly the historical isolates that were circulating 
in Europe during the period 1920-1970 and Group 2 are responsible for the outbreaks in the 90 
(Paton et al., 2000) (Fig.2). The outbreaks in the Netherlands and in the UK were caused by CSFV 
genotype 2.1 (Oleksiewicz et al., 2003;Graham et al., 2012). CSFV that belong to genotype 3 were 
mostly isolated from Asia (Sakoda et al., 1999) (Fig.2).  
 
Fig.2. Phylogenetic tree obtained with sequence data from 100 diverse CSF viruses, based on analysis of 190 
nt E2 sequence data-set adopted by (Paton et al., 2000). 
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Pestiviruses are small, enveloped positive single-stranded RNA viruses that contains one large open 
reading frame (ORF) flanked by non-translated regions (NTR) at the 5’ and 3’genome ends 
(Fletcher and Jackson, 2002). These viruses possess a genome of approximately 12.3 kb encoding a 
single polyprotein precursor that is processed into the four structural proteins C, Erns, E1 and E2 and 
seven to eight non-structural proteins: Npro, p7, NS2, NS3/NS2-3, NS4A, NS4B, NS5A and NS5B 
(Fig. 3) (Meyers and Thiel, 1996).   
 
 
 
Fig.3. Schematic description of the genome organization and virion structure of CSFV (Electron microscopy: 
Dr. H. Granzow and Dr. F. Weiland; design: M. Joern; Friedrich- Loeffler-Institute Insel Riems) (Beer. 
2007).  
The protein structure of pestiviruses is of importance for their immunogenicity, stability and 
infectivity. The most immunogenic are the envelope structural proteins Erns and E2 as they are 
specifically recognize by neutralizing antibodies (Paton et al., 1991). Antibodies against the NS3 
protein are also induced upon infection, but despite their ability to recognize different pestiviruses, 
they are not able to neutralize CSFV (Greiser-Wilke et al., 1992).   
The possession of a lipid envelope makes these viruses unstable to detergents and lipid solvents that 
easily destroy them (Moennig. 1992). Despite its envelope, CSFV virus remains infective in a 
relatively variable pH, in moist, excretion and fresh meat (Moennig. 2000), but is rapidly 
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inactivated by heat (Edwards et al., 2000). The survival of this virus is prolonged in rich of proteins 
environment especially in cooled or frozen products (Dahle and Liess, 1992).  
Clinical	Disease	and	Pathogenesis	
CSF is included in an OIE List as it is highly contagious disease that causes major economic losses 
in the pig industry (Moennig et al., 2003). The main route of infection is oronasal by direct or 
indirect contact. Contaminated feed (swill) and transmission with semen was reported as well 
(Floegel. 2000). The incubation period is approximately one week, but in the field the symptoms 
may become evident after longer period (Laevens et al., 1999). From the few experimental studies 
conducted with wild boar it seems that the course of the disease in domestic pigs and wild boar is 
similar (Artois et al., 2002). However, there are some difficulties with the clinical detection of this 
disease in wild boar due to their skin pigmentation the alternations that are caused by the disease are 
not so obvious. Furthermore, as other wild animals they try to “hide” the symptoms of severe 
disease.   
Depending on the virulence of the CSFV strain and the virus - host interaction several clinical forms 
could be observed (Paton. 2003). CSF clinical forms are very variable and this together with the 
extensive differential diagnosis and the usual complications by other diseases makes the detection 
of this disease very difficult (Moennig et al., 2003).Generally, the clinical forms of CSF can be  
classified as: post natal infections, including the subacute, acute and chronic form, trans-placental 
infections and persistent infections (Ganges et al., 2007).  
Acute	form	
Post natal acute course of the disease  is mostly observed in young pigs up to 12 weeks of age and 
last less than four weeks. The infected animals may either recover (transient infection) or die (lethal 
infection) (Moennig et al., 2003). This form is mainly result of infection with highly virulent CSFV 
and in young pigs the mortality rate may reach 100% (Lohse et al., 2011). CSFV is known to have 
a particular affinity for cells of the immune system (Susa et al., 1992). All leukocyte population can 
be deleted, but B lymphocytes are particularly sensitive. The depletion of the white blood cells 
(WBC) can be caused by necrosis or apoptosis and leads to severe leukopenia (Summerfield. 1998). 
Leukopenia is usually detected before the onset of vireamia and fever and neutralising antibodies 
will usually not appear before the leucopenia is overcome (Artois et al., 2002).   
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A usual finding during the acute form is pyrexia, usually higher than 40°C, anorexia, lethargy, 
depression, conjunctivitis, enlarged and discolored lymph nodes, respiratory signs and constipation 
followed by diarrhea, neurological signs as staggering gait and convulsion are frequently observed 
during this course of the disease (Moennig. 2000) (Fig.4). The typical haemorrhages of the skin are 
usually observed on the ear, tail, abdomen and the inner side of the legs and appear during the 
second week of the infection (Laevens et al., 1999) (Fig.4).  
 
Fig.4. Typical signs of acute CSF: haemorrhagical bleedings on the ear and neurological signs (hind legs and 
hunched up back) (photos-Lindholm). 
Similarly to the clinical picture, the pathological findings could also be variable depending on the 
genotype of CSFV. For example, changes such as necrotic lesions in the tonsils (Fig.5) and 
infraction of the spleen are often described in the literature from the 1970s when CSFV isolates 
belonged to genotype 1 (Mengeling and Packer, 1969). The recent genotypes of CSFV lead to 
changes mainly in the lymph nodes followed by necrotic lesions in the ileum and hyperaemia of the 
blood vessels in the brain (Uttenthal et al., 2001; Floegel-Niesmann et al., 2003). 
a) b)  
 Fig.5.Picture of a) tonsil obtained from not infected pig and b) tonsil of severely infected piglet no 33 from 
these studies with haemorrhagical bleedings and necrosis, the piglet was mock-vaccinated and challenged 
(own photos).  
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Chronic	form	
The chronic form of CSF always ends with death, but the animals may survive for 2 to 3 months.  
Although neutralizing antibodies are produced at the beginning of the infection they are present 
only temporarily as they are neutralized later by the virus (Depner et al., 1996). Chronic course of 
infection was defined when a pig was detected virus positive for more than 10 days (Uttenthal et al., 
2001). With this form pathological changes are less typical and haemorrhages and other 
characteristic for the acute form lesions could be missing. Typical are ulcerative lesions on the 
ileum, ileocecal valve and the rectum (Floegel-Niesmann et al., 2003; Moennig et al., 2003). 
Chronically infected pigs can excrete virus continuously for a long duration without to be 
discovered and in this way can play a crucial role in the epidemiology of CSF disease (Weesendorp 
et al., 2009a). 
Persistent	infection	
In pregnant sows, CSFV is able to cross the placenta and to infect the fetuses (Van Oirschot and 
Terpstra, 1977). The outcome of transplacental infection is dependent on the stage of gestation and 
the virulence of the virus. Early pregnancy infection results in stillbirth and mummification and 
infection about 50-70 days of pregnancy leads to birth of persistently infected pigs. These pigs are 
very important for the epidemiology of CSF disease as the animals have the virus that is excreted, 
but no antibodies against CSFV are present (Uttenthal et al., 2010a). The persistently infective 
piglets could live 2-11 months and during this time they are undetected and excrete a large amount 
of infective virus (Van Oirschot. 1979).   
Immune	Response	to	Classical	Swine	Fever	Virus		
The immunity against CSFV includes the three major types of resistance to infection: natural 
resistance, passively acquired immunity, and actively acquired immunity. Passive immunity will be 
reviewed separately as it is a major subject of the present thesis. Focus of this section will be mainly 
the active immunity (innate, cellular and humoral).  
Natural resistance to CSF infection occurs on a genetic basis. It was reported a changing clinical 
picture and mortality after infection with the same strain CSFV in piglets of the same age but 
different bred (Depner. 1997). The observed different resistance could also be due to the innate 
immune response. The innate response is a non-specific immune response that includes 
phagocytosis, activation of complement system and production of inflammatory and antiviral 
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cytokines as well as an acute-phase protein (APP) response. The APP response is an innate reaction 
that follows rapidly (6-12 h) after onset of any disease (Baumann and Gauldie, 1994). The APP 
response involves changes in the serum concentration of different proteins, mainly as a result of 
alternation in their hepatic synthesis and due to the influence of IL-1, IL-6, and TNF-α (Skovgaard 
et al., 2009). In pigs, haptoglobin and C-reactive protein (CRP) are considered the major APPs 
(Heegaard et al., 1998). CRP main function is to bind to the neutrophils and to activate the 
clearence of damage cells by phagocytosis. Another function is the activation of the classical 
compliment. It was suggested that early concentration of this protein might predict the outcome of 
CSF infection as high concentration are detected in the infected with highly virulent strains CSFV 
pig (Nielsen et al., 2010). In pigs infected with CSFV maintenance of CRP concentrations may role 
played in the modulation of monocytes and macrophages. Enhancement of the serum CRP 
concentration may be observed during the late stages of CSF due to the increase number of Kupffer 
cells that additionally are stimulated by IL-6 and IL-1 (Sánchez-Cordón et al., 2007).  
The understanding of cellular immune response is of major importance for the design of new and 
potent vaccines. Cellular immunity is accepted to be responsible for the early protection against 
CSF as the protection may precede the appearance of neutralizing antibodies while IFN-γ secreting 
cells are detected in the peripheral blood. It was shown a correlation between protection and 
production of CSF specific IFN-γ (Suradhat et al., 2001).The role of cytotoxic T lymphocytes 
(CTL) has been confirmed in several studies as well (Pauly. 1998; Armengol. 2002; Guzylack‐
Piriou et al., 2004). High and prolonged level of active CTL was reported from challenged with 
CSFV pigs that had very active CTL at 3 weeks post infection and that persisted up to day 74 post 
infection (Piriou et al., 2003). Furthermore, it was demonstrated that NS3 specific CTL are able to 
secrete IFN-γ (Rau et al., 2006). Very early activation of cellular immune response as 2 days post-
infection might be influenced by the way of inoculating the infection. For example, a higher 
generation of cell-mediated immune response was reported following intranasal and oral CSFV 
infection than after intramuscular inoculation (Piriou et al., 2003).  
Generally, neutralizing antibodies to CSFV may be detected earliest at two weeks after infection 
(Artois et al., 2002). Development of humoral immunity is very dependable on the virulence of 
CSFV. As the virus affects mainly the T and B lymphocytes, the development of virus neutralizing 
antibodies was shown to be spares in piglets infected with low virulent strains CSFV and non-
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existent in pigs infected with moderate or high virulent strains as the piglets succumb to the 
infection before the onset of humoral immunity (Lohse et al., 2012). Post intramuscular 
administration of live attenuated vaccines seroconversion is expected to be detected after 2 weeks 
(Van Oirschot. 2003b). As part of this PhD project a pilot study was performed vaccinating 12 4-
week-old piglets, 3 piglets were sacrificed every week, the antibody response was followed in the 
remaining pigs. As seen in fig 6 the first piglets were antibody positive in a whole-virus blocking 
ELISA at 10 to 17 days after vaccination. After 4 weeks the remaining 3 pigs were antibody 
positive (fig 6). 
 
Fig.6. Results obtained by ELISA used for serosurveillance in Denmark (Have. 1984) ) testing antibody 
response in 12 piglets vaccinated intramuscularly with C-strain (Riems) vaccine and followed for 4 weeks. 
At the beginning of each week 3 piglets were euthanized. Dash line represents the cut off value and all 
results < 70 are positive >70 are negative (own results obtained from the pilot study conducted at the 
beginning of the project). 
 Usually, humoral immunity after oral immunization appears one week later than after 
intramuscular vaccination (Chenut et al., 1999). B cells activation is stimulated by IL-4 which is 
produced by Th2 cells. This cytokine is accepted as the main indicator of antibody – mediated 
immunity (Paul. 1987). There is no information on how this cytokine is modulated during CSF 
infection.  
Presence of the three main immunoglobulins (IgG, IgM and IgA) was previously demonstrated in 
pig serum (Curtis and Bourne, 1971). IgG is the predominant class and based on gene sequence data 
the following subclasses were identified: IgG1, IgG2 (a & b), IgG3 and IgG4 (Furesz et al., 1998). 
IgG2 concentration in pig serum is 46-75% depending on the age of the pig, with higher percentage 
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detected in younger pigs (Bokhout et al., 1986). IgG1 is the other major immunoglobulin class in 
pigs. The recently conducted comparative study with live attenuated and live recombinant vaccine 
against CSF, showed that after oral vaccination without challenge these vaccines differ in their 
IgG1 and IgG2 activation (Renson et al., 2012). It was previously reported that the IgG1:IgG2 ratio 
in pigs is a good indicator of the adaptive immunity potentiation toward a Th1 or Th2 response 
(Crawley et al., 2003). Predominance secretion of isotype specific IgG1 antibodies suggests 
activation mainly of the humoral part of the immune response and oppositely major detection of 
IgG2 is related to activation of the cellular immune response (Fig.7).  
 
 
 IgG1 
 
   IgG2 
 
Fig.7. Schematic presentation of cellular and humoral immune response activation in relation to IgG1 or 
IgG2 predominant secretion (adapted by http://www.quora.com).  
Infectivity	of	Classical	Swine	Fever	Virus	
Different factors have been discussed to influence the course of CSF infection (Dahle and Liess, 
1992). Specific host-virus interactions determine disease development and clinical outcome. Host 
factors such as: age, genetic background and immune status, herd sanitary status as well as strain 
virulence are known to play significant role for the course of the disease (Lohse et al., 2012).  
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Characterizing virulence has been attempted in various ways: case fatality, clinical and pathological 
signs, characterization in cell culture or variations in the genome. Based on experimental infections 
it was found a correlation between clinical scores (CS) (Wood et al., 1988), fever and virulence, but 
no qualitative or quantitative difference was detected in the RNA replication and protein synthesis 
among the different strains (Mittelholzer et al., 2000). With the same study it was proposed a 
system for assigning a virulence based on CS: CS>15 and body temperature > 41°C as a highly 
virulent strain CSFV and CS of 5-15 as moderate virulent. This system is used by many laboratories 
and is applied to provide comparability between experiments. However, it is arguable whether this 
system is precise. Oppositely to the European isolates from the late 1990s that belong to genotype 
2.3 and produce delay clinical signs, the historical highly virulent CSFV from genotype 1 (Koslov, 
Alfort, Margarita etc.) cause acute form of the disease with high mortality very shortly, generally 
during the first week after infection (Kaden et al., 2001b; Lohse et al., 2011; Tarradas et al., 2011). 
This is usually insufficient time to develop a clear clinical picture and CS >15 can be rarely 
reached.  Thus, complex factors and parameters additionally to the CS system should be included to 
correctly evaluate CSFV virulence. (Floegel-Niesmann et al., 2003), introduced pathological scores 
as an additional parameter for detailed characterization of CSFV. The same authors, proposed 
modified CS schema including three other parameters such as: case fatality at 3 weeks post 
infection, leukocyte count between 0-14 days post infection and homologue CSF antibody titer at 
14 days post infection (Floegel-Niesmann et al., 2003).   
Host factor can significantly attenuate the virus and produce variable disease outcomes. For 
example, the described by several authors (Mittelholzer et al., 2000; Mayer. 2003; Durand et al., 
2009) as highly virulent CSFV-Eystrup strain in other studies conducted with pigs from the same 
breed depending on the age and the sanitary status caused severe (Uttenthal et al., 2008), moderate 
(Rasmussen et al., 2007) or mild disease (Nielsen et al., 2010). 
The role of the inoculation dose on the virulence of CSFV is a subject of discussion. In a previous 
study pigs were infected with high (106 TCID50 ) or low (103 TCID50 ) doses of highly CSFV strain  
Alfort and clinically no difference between the two groups pigs was observed. It was suggested that 
the inoculation dose is unlikely to significantly influence the virulence, thus the properties of the 
virus and the host were suggested to be the major factors responsible (Mittelholzer et al., 2000). 
Another study evaluated the effect of strain and the inoculation dose on within-pen transmission and 
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found that with low dose of moderate strain no infection occurred, but with moderate and high dose 
the outcome of the infection was the same and similar to that with high virulent strain that had the 
same doses (Weesendorp et al., 2009b). According to Dahle and Liess, 1995, the clinical course is 
dependable on the inoculation dose of CSFV. Oppositely, Depner et al., 1997 observed that if the 
critical infectious dose is present the infection takes its course without a significant difference.  
Laboratory	Diagnostic	Methods	for	Detection	of	CSF	
The key to CSF control during an outbreak is the early identification of CSF infected herds (Dewulf 
et al., 2004). Diagnostic methods for detection of CSFV are mainly divided into antigen or antibody 
detecting and virological or immunological methods. As all of the existing tests are not possible to 
be applied during an outbreak the selection of the proper assay for the exact purpose is very 
important. Detection of virus or viral nucleic acid in whole blood and of antibodies in serum are the 
methods of choice for diagnosing CSF in live pigs while detection of virus, viral nucleic acid or 
antigen in organ samples is most suitable when the pig is dead (OIE. 1998).  
Reverse transcriptase-Polymerase chine reaction (RT-PCR) is accepted as the most powerful 
diagnostic tool for early diagnostic of CSF (Paton et al., 2000; Dewulf et al., 2004). After extraction 
from the diagnostic sample the RNA has to be transcribed to complimentary (cDNA) that then can 
be amplified by PCR. Evaluation of PCR or RT-PCR can be performed by agarose gel 
electrophoresis or by real time techniques (RT-qPCR). However, with this test is not possible to be 
shown real viraemia and only by virus isolation (VI) on cell culture or infectious studies in pigs can 
prove that the virus is alive and able to replicate. Another disadvantage of RT-PCR method is that 
this technique is extremely vulnerable to false negative and false positive results. False negative 
results can arise when the nucleic acid is degraded or when the reaction mixture contains inhibitors. 
Due to its high sensitivity, false positive results may arise from contamination (Greiser -Wilke et 
al., 2007) 
The most commonly used tests for CSF antibodies are enzyme-linked immunosorbent assay 
(ELISA and) virus neutralization test (VNT).The VNT test is able to detect positive piglets earlier 
than the antibody ELISA test, but it is rather laborious and time consuming (Greiser -Wilke et al., 
2007). The VNT is compulsory in the EU for confirmation of positive results obtained by CSF 
antibody ELISA as it can differentiate between the Pestiviruses.   
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A large comparison of diagnostic tests was performed by Dewulf er al., 2004 and the results are 
presented graphically in Fig. 8. In order to choose the right test it should be taken in consideration 
that CSFVs with different virulence may produce viraemia of variable duration and intensity 
(Depner et al., 1994). It has also been suggested that the sensitivity of genome detecting test (RT-
PCR) may vary for different virus strains (De Smit. 2000a). Another problem is the cross reactivity 
that exist between CSFV and the other Pestiviruses (BVDV and BDV) (Wieringa-Jelsma et al., 
2006). Thus, it is of importance to take into consideration the prevalence of these viruses in the pig 
population tested from the affected area. The use of appropriate primers and probes are necessary 
for the performance of specific and sensitive test. 
 
Fig.8. Graphical presentation of the average duration of the test positive period for the different diagnostic 
techniques in comparison to virus isolation (VI) in whole blood. Average start and end of the positive period 
is given in parenthesis. The zero indicates when a positive sample was detected by VI (Dewulf et al., 2004).   
Strategies	for	prevention	and	control	of	CSF	in	EU	
In the 1970s, CSF was endemic in European Union (EU) Member States and routine prophylactic 
vaccination was a commonly practiced control measure (Saatkamp et al., 2000). During the 1980s, 
EU aimed to eradicate CSF from the entire union. Thus, in order to ensure that the same measures 
for prevention and control of CSF disease are applicable for all Member States the different national 
policies to controls CSF were replaced by Community legislation (Anonymous. 1980). Since then, 
prophylactic vaccination is not allowed and in case of outbreak strict control sanitary measures are 
used. The following measures usually are applied: restriction in movements, establishment of a 
protective (of minimum 3 km) and surveillance zone (of minimum 10km) around the infection, 
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stamping out of the infected herd and pre-emptive culling of animals that are suspected but not 
proved to be infected (Terpstra and de Smith, 2000). For wild boar, bait vaccination in case of 
emergency is practiced in some areas (Laddomada. 2000; Kaden. 2001a).  
Despite the strict control policy, complete eradication of CSF in EU is unlikely. The disease is still 
present in wild boar that serves as a reservoir and spreads sporadically the infection to domestic 
pigs (Edwards et al., 2000). The wild boar is non-selective feeder and does not rely on special food 
(Graves. 1984). Additionally, this species possesses a unique reproductive strategy such as: delay 
heat, weight-dependable fertility and reproductive season of 6-8 months (Artois et al., 2002). Due to 
these physiological characteristics as well as hunting practices, wild boar has dramatically increased 
in number and range and thus, CSF virus eradication in this population is very difficult (Griot et al., 
1999) (Laddomada et al., 1994). Giving the ecological elasticity of the wild boar, hunting pressure 
might be very ineffective in attempting to control population densities and in this way to control 
CSF (Artois et al., 2002). It was revealed that oral baits are eaten mainly by older animals, but in 
infected population young animals are targeted, therefore to be effective this strategy needs an 
improvement (Laddomada. 2000; Kaden. 2001a). 
In the late 90s, there were numerous outbreaks of CSF in the EU. The outbreak in the Netherlands 
in 1997/1998 was one of the most costly with a direct lost estimated to US $ 2 billion. The reasons 
for these serious consequences were mainly the late detection of the disease, the stamping-out 
strategies and the movement restriction. The movement restriction led to a culling of enormous 
number of completely healthy pigs, for example, finishing pigs that grew up and had to be killed as 
they could not be transported to the slaughter houses. The experience of this outbreak showed that 
the effectiveness of eradication of CSF is related very much to educating the people involved in the 
pig production business (Elbers. 2001). It highlighted the need for training the field service in 
disease recognition in order to increase the speed with which the infection will be diagnosed 
(Terpstra and de Smith, 2000). The human role in the prevention of CSF is of a significant 
importance especially in the new EU countries where commercial pig farms are a low percentage 
and most pigs are kept in traditional, family owned backyard farms for self-consumption (Blome et 
al., 2006). Due to the enormous cost of the many outbreaks and the ethical aspects of culling large 
number of healthy pigs the current policy of strict sanitary measures is evaluated. Furthermore, a 
strict stamping out policy without vaccination might prolong the duration of CSFV epidemics as the 
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shedding and the spread of the virus to other herds could exist for a long time before the infection is 
detected clinically and serologically (Uttenthal et al., 2001).   
Thus, additionally to the described above measures, emergency vaccination as an alternative control 
strategy both for domestic and wild boar was recently very intensively discussed (Nigsch and 
Depner, 2012). Emergency vaccination is allowed in EU, but only under exceptional circumstances 
and following an approved emergency plan (Anonymous. 2001). However, emergency vaccination 
of domestic pigs was almost never implemented (Blome et al., 2012). A vaccine that is going to be 
applied in emergency situation should be more effective than vaccines used for prophylactic 
purposes. The emergency vaccine should be very potent, have to induce sufficient protection very 
early at 1 week post vaccination and should be able to prevent congenital infection. Like pre-
emptive culling, the aim of the emergency vaccination strategy is to reduce virus spread from an 
infected herd. Within current legislation possible emergency vaccination strategies include: 
suppressive vaccination, where animals in a zone around an infected herd are vaccinated with live-
attenuated vaccine and subsequently slaughtered (vaccinate-to-kill) or 2) protective vaccination, 
(vaccinate to live) where a marker vaccine is used (Graham et al., 2012).  Effective and safe 
commercial vaccines are only the existing conventional modified live attenuated vaccines, but they 
contain complete CSF virus and due to this after vaccination it is impossible serologically to 
differentiate infected from vaccinated pigs. Vaccinating country is not able to prove serologically 
that the infection is not present what restricts their trade with pigs and pig products (Moennig. 
2000). A territory can be accepted as a CSF- free if some requirements are fulfilled (OIE. 1998). 
There should be an absence of CSF for at least two years. One year should be passed after the last 
affected animal was slaughtered if the control measures were stamping out with vaccination or six 
months after slaughter if no vaccination was implemented. Thus, to ease the pig trade a new marker 
vaccine that allows detection of infection in vaccinated animals (DIVA) is needed. Furthermore, an 
implementation of marker vaccine would add very important information on the situation in wild 
boar and feral pigs as the spread of the infection can be followed in the infected population.  
2).	Short	Review	of	the	Existing	Licensed	Vaccines	against	Classical	Swine	Fever	
Modified	live	vaccines	
Vaccines can be divided into 2 large subgroups depending on their ability to replicate in the host. 
Killed vaccines are based on full virus suspensions that are chemically inactivated before 
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adjuvation. Live vaccines are attenuated so that they replicate in the host but not sufficiently to 
cause a disease. For CSF, killed vaccines have been used. However, these vaccines were able to 
prevent the clinical manifestations of the disease but not the infection. Thus, the inactivated 
vaccines were replaced by the modified-live attenuated vaccines (Ferrari. 1992). At present the 
mostly used live attenuated vaccines are based either on Chinese (C) strain, on the French cell 
culture adapted Thiverval strain or Japanese quinea-pig exaltation-negative strain (GPE-). The 
Thiverval strain has been obtained from the virulent Alfort strain and attenuated through more than 
170 serial passages at a low temperature (29-30°C). As the C-strain vaccine is produced in many 
companies the description below is on the registered C-strain for commercial use.  
The C-strain, modified live vaccine virus is derived from genotype 1 CSFV. It induces sterile 
immunity (prevents replication and transmission of the challenge virus) and vaccination with this 
vaccine leads to very high level of protection within a week post vaccination (Van Oirschot. 
2003b).  The C-strain vaccine can elicit protective immune response against all CSFV genotypes 
(Suradhat and Damrongwatanapokin, 2003). The origin of the C strain is not exactly known. Firstly, 
the vaccine was attenuated by hundreds of serial passages in rabbits, but subsequently to make it 
cheaper and to avoid some disadvantages of using live organisms (Lorena et al., 2001), the vaccine 
virus that is used in Europe was adapted to growth in cell cultures (Terpstra et al., 1990). The 
adaptation of the vaccine to different cell cultures increased the titer of the vaccine without reducing 
its immunogenicity (Rivero et al., 1988).  This vaccine has a U-rich insertion of 13 continuous 
nucleotides in the 3`non-coding region compared with that of virulent strain and it is speculated 
whether this insertion is involved in reducing the virulence of the vaccine (Moormann et al., 1996).  
C-strain has proven to be a very safe vaccine for pigs of any age and breed. Only mild fever and 
neither affect on the growth nor local reactions at the site of application have been reported. The 
possibility for reversion to virulence is accepted as insignificant as the vaccine virus remains 
avirulent after 30 passages in pigs (Qiu et al., 2005). The vaccine virus primarily replicates in the 
tonsils (Lorena et al., 2001). 
C-strain vaccine induces detectable neutralizing antibodies at 2-3 weeks post vaccination (Fig. 9), 
here shown by our own unpublished results following piglets after C-strain vaccination. The 
antibody response of the pigs was measured against the homologues virus (C-strain) as was used for 
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vaccination. The antibodies reach maximum levels at 4-12 weeks post vaccination and they are 
present at least for 6-18 months (Precausta. 1983; Terpstra and Wensvoort, 1987; Kaden et al., 
2008).  
 
Fig.9 Results obtained by Neutralization test from 12 piglets vaccinated intramuscularly with C-strain 
(Riems) vaccine. The piglets were followed for 4 weeks and at the beginning of each week 3 piglets were 
euthanized. (Rangelova, unpublished). 
However, protection against a virulent challenge was observed during the first week post 
vaccination before detection of antibodies (Van Oirschot. 2003b). This early protection after 
vaccination with C-strain vaccine was shown to be due to the induction of cell-mediated immunity. 
CSFV-specific IFN-γ secreting cells were detected in pigs vaccinated with C-strain, as early as 6 
days post vaccination. During the first week post vaccination no or very low level of neutralizing 
antibodies were detected (Suradhat et al., 2001). The onset of protection following C-strain 
vaccination is dependable on the administration method. It was demonstrated that the establishment 
of complete clinical protection after oral immunization was 10 days post vaccination (Kaden. 
2001b). When C-strain vaccine was administered parenterally some protection was detected already 
at 2-4 days post vaccination and complete at day 7 post vaccination (Van Oirschot. 2003b; Renson 
et al., 2012).   
	Subunit	marker	vaccines	
Subunit vaccines are inactivated vaccines, but contain only part of the virus, usually E2 protein 
(Uttenthal et al., 2001). The application of subunit vaccines may result in some local tissue 
reactions at the injected sites due to the added adjuvant, but since they are killed vaccines they are 
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very safe (Bouma et al., 1999; Depner et al., 2001). Two marker subunit vaccines against CSFV 
have been licensed, one from Bayer, Leverkusen, Germany (BAYOVAC® CSF Marker), the other 
one from Intervet, Boxmeer, The Netherlands (PORCILIS® PESTI). Both vaccines are based on the 
envelope E2 glycoprotein of the CSF virus which has been produced in insect cells by a baculovirus 
expression vector (Hulst et al., 1993; Hulst. 1994; Van Rijn et al., 1996). Although suitable for 
prophylactic vaccination, these vaccines showed insufficient efficacy when administrated in 
situations mirroring an emergency and thus, they are withdrawn from the market. The numerous 
vaccination-challenge experiments showed that the vaccines were safe, but some problems were 
recorded with these two subunit vaccines. As these vaccines do not replicate as live vaccines they 
cannot be applied for bait vaccination of wild boar. Vaccination of pregnant sows did not prevent 
transfer of challenge virus from the sow to the fetuses (Depner et al., 2001). It was reported that in 
order to achieve a sufficient efficacy, there should be a booster immunization 4 weeks after the first 
primer vaccination (Dewulf et al., 2000). According to Uttenthal et al. 2001, there was no sufficient 
protection post challenge as viraemia was still detected in some piglets challenged 21 days post 
vaccination, pigs challenged before 21 days after vaccination had a very low protection. 
Furthermore, with regard to prevention or reduction of transmission of the infective virus, it has 
been revealed that the majority of vaccinated in-contact pigs become infected when pigs were 
challenged 7 days post vaccination (Bouma. 2000). Reduction but not prevention of vertical 
transmission after intranasal or contact challenge with moderate - virulent strain of CSFV was 
demonstrated (De Smit et al., 2000b). These studies showed that E2-subunit marker vaccines are 
not efficacious for use as emergency vaccine. Thus, the only vaccine on the market is the live C-
strain vaccine. However, as will be describe below, the disadvantage of the attenuated live vaccines 
is that the antibody pattern induced by these vaccines resembles that of reconvalescent animals 
surviving from the infection, so that vaccinated and field-virus-infected animals cannot be 
differentiated serologically. Thus, the control of CSFV outbreaks in domestic pigs as well as in wild 
boar could be significantly enhanced if a safe and efficient DIVA vaccine is available. In the next 
section the principal of DIVA vaccines will be described.   
3).	Introduction	to	DIVA	Vaccines	
The term Differentiation of Infected from Vaccinated Animals (DIVA) was introduced in 1999 
(Van Oirschot. 1999). The general principal that the DIVA vaccines exploit is based on the 
difference of the antibodies induced after vaccination with the DIVA vaccines and on these induced 
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after infection with wild CSFV (Fig. 10). As the main purpose is to detect infection rather than to 
distinguish between vaccinated and infected animals it was suggested that “Differentiating Infection 
in Vaccinated Animals” might be a more accurate description (Uttenthal et al., 2010b).   
 
Fig. 10 Principle of vaccination with DIVA vaccine (Uttenthal. Å, with permission). 
In general, there are three feasible marker design strategies: 
1). “negative marker” - there is an absence of antigenic epitope, domain or protein compared with 
the wild-type virus 
 2). “extrinsic positive marker”- an extrinsic immunodominant epitope or protein is included in a 
potent vaccine, these vaccines are used to prove a good seroconversion to the vaccine, but they do 
not have DIVA potential  
3). “intrinsic positive marker” - an immunogen or epitope that is from the virus itself but induce a 
different antibody pattern from that of the wild type. 
Almost all candidate DIVA vaccines were constructed as “negative marker” vaccines and their 
companion diagnostic test was designed to detect antibodies against the absent in the vaccine 
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protein (Dong and Chen, 2007). The three proteins inducing detectable antibodies are: E2 (major 
immunogen, neutralizing activity), Erns (low or no neutralizing activity) and NS3 (no neutralizing 
activity). Among Pestiviruses the NS3 protein has a high genetic stability and as there is a 
possibility for infection with BVDV and BDV viruses in pigs, detection of NS3 specific antibodies 
is not suitable for DIVA diagnostic (Beer. 2007). Thus, DIVA vaccines against CSFV are mainly 
based on the most immunogenic E2 enveloped protein (Hulst. 1994). The new chimera vaccine 
“CP7_E2alf” is also constructed on the principle of a “negative marker” using only E2 from CSFV.  
Discriminatory Tool  
Without sensitive and specific discriminatory tool a vaccine cannot be implemented as a DIVA 
vaccine. ELISA was the major tool that up to now has been developed as DIVA test. 
Immunological	DIVA	tool	
ELISA test for the detection of CSFV antibodies directed against E2, Erns or NS3 protein are 
commercially available. E2-ELISAs are used in the field as conventional screening test for the 
detection of CSFV infection on a herd bases (European Union (EU). 2002). Erns blocking ELISA 
test that detects specific CSFV Erns antibodies was designed as accompanying discriminatory tool to 
the above described E2 subunit vaccines. The principle of this test is that the Erns antigens expressed 
in baculovirus expression system and the serum of antibody positive pigs competes with several 
monoclonal antibodies targeting Erns (Uttenthal et al., 2010b). The only commercially available Erns 
ELISA is the PrioCHECK® CSFV test. Initially, the test had some deficiency regarding its 
sensitivity and specificity (Schroeder et al., 2012). 
Genetic	DIVA	tool	
The ELISA discriminatory test is possible after induction of antibodies that with CSFV are not 
expected before 7 days post infection. This early window phase for detection with discriminatory 
ELISA assay may be covered by detection of viral genome. The recently published RT-PCRs 
(Hoffmann et al., 2005; Hoffmann et al., 2006), permit direct differentiation between vaccinated 
and infected pigs. The RT-PCR assay specific for all pestiviruses (panpesti-specific) detects both, 
the vaccine strain and the wild CSFV (Hoffmann et al., 2005; Liu et al., 2009a). The CSFV specific 
RT-PCR assay detects only the infected with CSFV pigs (Hoffmann et al., 2006).  
 
 
 
 
 
 
34 
 
Different	types	of	DIVA	vaccines	against	CSFV	
The next generation of marker vaccine candidates against CSF is divided in several groups and their 
characteristics are summarized in Table.1. 
Table 1 Different types of DIVA vaccines (Beer. 2007). 
Type of CSFV vaccine 
 
Examples Disadvantages 
CSV peptide vaccines 
 based on E2 antigen 
 
Mono-peptide-vaccines 
Multi-peptide-vaccines 
Fail to provide complete protection and not 
suitable for oral immunization 
DNA vaccines Immunization with expression plasmids 
containing complete or partial CSFV-E2-
encodin sequence  
(encoding sequence of immunostimulating 
factors could be also included) 
High doses and several applications are 
needed to achieve protection against mortality 
Viral vectors vaccines Expression of E2 (complete or partial) into 
the genome of other viruses 
As with all live attenuated viruses there is a 
concern about recombination and reversion to 
virulence 
Chimeric pestiviruses -CSFV-E2-encoding sequences are inserted 
into a BVDV backbone 
-BVDV or BDV sequences are inserted into a 
CSFV vaccine backbone  
As with all live attenuated viruses there is a 
concern about recombination and reversion to 
virulence 
Trans-complemented 
replicons 
-Packaged replicons with a deletion in the Erns
encoding region 
-Packaged replicons with a deletion in the E2-
encoding region 
Protection depends on the application route 
and the best obtained results are after dermal 
injection 
 
4).	Challenges	of	Early	Life	Vaccinology	
One of the major challenges in vaccinology is the development of products that are able to induce 
protective immunity in the early life period. It is very important that biological products are 
designed to provide protection of the youngest individuals. However, this is a particularly 
challenging task given the fact that pig’s immune system is not completely developed before 4 
weeks of age (Povey C. 1997). Additionally to the immature porcine immune system, the presence 
of inhibitory concentrations of passive antibodies obtained trough colostrums from immune mothers 
during the early life of pigs imposes a further barrier to effective early life vaccination against 
CSFV in the field (Launais et al., 1978; Suradhat et al., 2007). There are different mechanisms for 
MDA to influence the active development of B and T- cells. Generally, administration of vaccine 
antigen in a host may result into the formation of antigen-antibody complexes (Fig.11). MDA bind 
to specific B-cell vaccine epitopes, blocking the access of the pig’s own B cells to such epitopes and 
the level of this inhibition depends upon the vaccine antigen/MDA concentration ratio. The antigen-
antibody immune complexes are further either processed by the piglet antigen presenting cells 
(APC) or destroyed by the reticuloendothelial system. Thus, peptide presentation at the APC leads 
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to priming of the cellular immunity (CD4 or CD8 T cells), despite the inhibition of the humoral 
immunity. However, this priming could be inhibited by high levels of MDA that could entirely 
neutralize the vaccine virus, which will not be able further to replicate and this will lead to 
significant reduction of the vaccine effectively (Siegrist. 2001).      
 
Fig.11 Influence of passively transferred antibodies on induction of vaccine response (Siegrist. 2001).  
In case of CSFV outbreak, vaccination at earliest possible age is needed. However, in population 
previously vaccinated the presence of maternal immunity may cause some complication. MDA has 
been shown to affect antibody responses to vaccination against CSFV (Vandeputte et al., 2001). As 
mentioned above, the level of this influence is very much dependable on the MDA concentration. 
For CSF, it was demonstrated that the half life of MDA depends on the time point of the mother’s 
vaccination. The earlier the mothers are vaccinated the higher are the antibody titers at the time of 
colostrums production that they transfer to the piglets. Fig. 12 shows the relation between sows 
antibody concentration and the levels of the obtained with colostrums antibodies in the present 
study. All piglets were antibody negative prior to uptake of colostrums but at the next sampling 3-7 
days after birth the piglets had antibody titers close to what was seen in the mothers. The longest 
persistence of CSF MDAs was reported when sows were vaccinated before pregnancy with several 
doses (Launais et al., 1978; Suradhat and Damrongwatanapokin, 2003). Studies have shown that 
 
 
 
 
 
 
36 
 
following oral immunization MDAs are present for longer time than after intramuscular 
immunization (Müller et al., 2005; Suradhat et al., 2007). According to Launais et al. 1978, the 
most successful period for vaccination is from 5 to 8 weeks of age, as during this time the pigs still 
have MDAs with moderate concentrations that protect them, but do not interfere with the efficacy 
of the vaccine. It was demonstrated that CSF vaccine induced complete protection when the MDAs 
neutralization titer at the time of the vaccination was lower than 64 (Suradhat et al., 2005). This was 
also confirmed in our studies when using the “CP7_E2alf” vaccine (Rangelova et al., 2011). 
 
Fig.12. Results obtained by blocking in house ELISA (Have,P. 1984 ) and depicted as average optical 
density (OD) % at farrowing in four sows vaccinated intramuscularly with C-strain at four weeks before 
farrowing and in their piglets after uptake of colostrums. Cut off value is 70 and results ≥ 70 are negative and 
< 70 are positive. (Rangelova, unpublished) 
Thus, vaccine type, age of the pig at vaccination, administration route, dose and presence of 
adjuvant are factors that influence also the early life antibody response to vaccination (Siegrist. 
2007). Different strategies such as: choosing the right type vaccine, addition of adjuvant and 
increasing the vaccine dose could be used to enhance efficacy in presence of MDAs. However, the 
safety profile of a vaccine could be compromised if these strategies are not appropriately balanced. 
Thus, the identification of effective and safe early life strategies requires specific research approach 
in the search for the right vaccination schedule that will provide efficacy/safety balance.  
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5).	The	New	Third	Generation	Chimeric	Vaccine	Candidate	“CP7_E2alf”		
The chimeric “CP7_E2alf” virus was constructed using a complimentary DNA (cDNA) clone of 
cytopathic BVDV type 1 strain CP7, which is avirulent for pigs. The entire E2- encoding region, of 
CP7 which is the most immunogenic protein in the structure of Pestiviruses, was replaced by that of 
CSFV strain Alfort 187 (Fig.13) (Reimann et al. 2004).   
 
Fig.13 Schematic representation of the engineered construct of “CP7_E2alf” (Reimann et al., 2004). 
Different from the conventional vaccines, marker vaccines must fulfill both the general demands 
(safety, efficacy, clinical protection, etc.) and special requirement (induction of characteristic 
antibody pattern). Moreover, as these vaccines are intended for emergency vaccination there is a 
higher demand for very fast onset of solid immunity.  
Safety	and	Efficacy	of	“CP7_E2alf”		
The safety and the efficacy of “CP7_E2alf after intramuscular or oral administration were addressed 
in several published studies (Reimann et al., 2004; Koenig et al., 2007; Leifer et al., 2009; Tignon et 
al., 2010; Blome et al., 2012; Gabriel et al., 2012; Rangelova et al., 2012). In the frameworks of 
these studies, the safety was tested in different age categories ranging from approximately 1-8 
months. The pigs were observed for 14 to 98 days periods. None of the animals showed CSFV-
associated clinical signs or pathological lesions, fever or leucopenia, even after triple vaccination. 
Moreover, no local reactions at the site of injection were observed in any of these experiments.  
The efficacy studies used for the challenge infections the highly virulent CSFV strains. These 
strains were reported to cause severe clinical signs and 100% mortality in naïve piglets during the 
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first week post infection (Mittelholzer et al., 2000). It was shown that intramuscular or oral 
vaccination with “CP7_E2alf” resulted in full clinical protection when challenge was performed 
very shortly after vaccination, which is prerequisite for the use as an emergency vaccine. Already 1 
week after intramuscular vaccination was demonstrated complete prevention of morbidity, even 
with 1:10 diluted vaccine (Leifer et al., 2009). Although, an early protection against highly virulent 
strain CSFV after oral vaccination is a difficult task to achieve due to the late onset of humoral 
immunity (Greiser -Wilke et al., 2007), “CP7_E2alf” performed even better than the “gold-
standard” C-strain “Riems” when the piglets were challenged 14 days post vaccination (Leifer et al., 
2009).The same tendency was observed with oral “CP7_E2alf” vaccination that resulted in 100% 
complete protection 14 days post challenge while with  C-strain  only 83% of  the pigs were 
protected (Blome et al., 2012).   
Concerning prevention of viraemia, no sterile immunity was induced after oral vaccination with 
“CP7_E2alf” as it seems that a limited replication of the challenged virus occurred based on the 
real-time PCR (RT-PCR) results and on the positive virus isolation from the blood sample of one 
vaccinated pig (Blome et al., 2012). More studies from the same group reported complete lack of 
virus isolation from nasal swabs and leukocytes and only limited genome detection in 
intramuscularly vaccinated pigs (Reimann et al., 2004; Koenig et al., 2007; Leifer et al., 2009; 
Gabriel et al., 2012). The absence of live virus is very promising for the future use of this vaccine.  
Antibody titers elicited by one shot intramuscular and oral vaccination with “CP7_E2alf“ 
demonstrated to be stable for at least six months as with the exception of one orally vaccinated pig, 
protection against mortality and clinical signs was proven (Gabriel et al., 2012).  
Transmission	of	challenge	virus	to	contact	animals	
Full protection against transmission of infection virus to in-contact domestic pigs and wild boar was 
shown when the challenge was carried out 21 days post oral vaccination (Koenig et al., 2007; 
Blome et al., 2012). In the same study, challenge at 14 days post vaccination resulted in clinically 
apparent CSF and 100% mortality between 15 and 22 day post challenge. Intramuscular vaccination 
seems to provide very early protection against transmission. When challenge was given as early as 1 
week post vaccination no infectious virus was detected in the vaccinated animals (Leifer et al., 
2009), however to prove the lack of excretion of challenge virus contact animals should be 
included.  
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DIVA	potential	
Erns differentiation 
Being a marker vaccine candidate, “CP7_E2alf” was evaluated for its DIVA potential. This vaccine 
allows a limited replication, which was proven to be insufficient for transmission of the challenge 
virus and is a very useful property of “CP7_E2alf “in relation to its DIVA potential. Earliest 
seroconversion was reported at day 7 post challenge in wild boar orally vaccination (Koenig et al., 
2007). Generally, seroconversion to the challenge virus Erns following both oral and intramuscular 
vaccination was reported at day 10 post infection and at day 21 all tested pigs were positive 
(Reimann et al., 2004; Koenig et al., 2007; Leifer et al., 2009). DIVA potential of “CP7_E2alf” was 
also demonstrated in domestic pigs positive for maternal C-strain antibodies (Manuscript 2 in this 
thesis). No seroconversion to the vaccine Erns specific antibodies was shown even after triple oral 
vaccination (Blome et al., 2012) 
Genetic differentiation 
The two described above RT-PCRs (Hoffmann et al., 2005; Hoffmann et al., 2006), seems to be a 
promising accompanying to “CP7_E2alf” discriminatory tool as it permits direct differentiation at 
early time point between “CP7_E2alf” and CSFV when it was targeted the CSFV 5’UTR region 
(Tignon et al., 2010).  
Ecotoxicity	
As this vaccine is genetically modified organism (GMO) and it is a live attenuated vaccine some 
concerns were expressed about its release in the environment. The risk for the environment linked 
to the use of “CP7_E2alf”however, seems negligible as this chimeric virus proved to be completely 
avirulent in vaccinated target and non-target species (König et al., 2011) even in very high repeated 
dose.“CP7_E2alf” is constructed on DIVA principle and there is a validated ELISA method to 
differentiate this chimeric virus from the wild type CSF and BVD viruses. Thus, tracing the virus in 
the environment is possible by easy and reliable methods. Possibility for genetic recombination 
between the vaccine BVDV with other field BVDVs (Dong and Chen, 2007) is very low as there 
was observed only limited viral replication of “CP7_E2alf” in the target species and incidents of 
BVDV infections in pigs and wild boar are very rare.   
 
 
 
 
 
 
40 
 
Project	Aims	
 
This general literature review aimed to give an overview of CSF as a disease and the existing 
strategies for controlling an outbreak as well as a possible implementation of new measures in the 
fight against this disease. Vaccination with effective and safe DIVA vaccine could be a solution to 
confine an outbreak and to ease the meat trade. However, in many countries C-strain vaccine is used 
either for prophylactic vaccination or for emergency baits vaccination and interference of MDA 
with the efficacy of a new DIVA vaccine is very possible. 
Thus, the general aims of this project have been: 
 Evaluation of the possibility for implementation of a new live chimeric marker vaccine in 
population previously vaccinated with modified live vaccine. 
 Investigation of efficacy of  chimeric marker vaccine “CP7_E2alf” in preventing clinical 
sings and mortality in 5 or 8 weeks old piglets positive for C-strain MDA. 
 Evaluation of DIVA potential of “CP7_E2alf” in piglets with MDA. 
 Investigation of the immune modulation post vaccination with C-strain live attenuated 
vaccine and with “CP7_E2alf. 
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a b s t r a c t
Marker vaccines offer the possibility to differentiate classical swine fever (CSF) infected from CSF vacci-
nated animals based on serology and their implementation will ensure free trade with pigs. Therefore,
new generations of promising marker vaccines have been developed, among them the chimeric vaccine
CP7 E2alf. However, in populations previously vaccinatedwith live attenuated vaccines like the C-strain,
passive immunity throughmaternal antibodies can interferewithefﬁcacyofCP7 E2alf vaccination. There-
fore, the efﬁcacy of CP7 E2alf was examined in piglets from sows vaccinated once intramuscularly with
C-strain vaccine 4weeks before farrowing. Thus, these piglets were vaccinated intramuscularly with
CP7 E2alf at the age of 5 or 8weeks. Subsequently, the piglets and their mock-vaccinated littermate con-
trols were challenged 2weeks post vaccination with highly virulent Classical swine fever virus (CSFV)
strain “Koslov”.
CP7 E2alf provided clinical protection upon challenge as no severe clinical signs or mortality was
observed in the vaccinated piglets. Post mortem examination revealed pathological changes associated
to CSFV only in the mock-vaccinated piglets. No infectious CSFV could be isolated from the tonsils of the
vaccinated piglets. Two weeks after vaccination at the time of challenge, the vaccinated piglets only, had
an increase in the ELISA antibody titer.
Interestingly, the maternally derived immunity in the mock-vaccinated control piglets seems to neu-
tralize the challenge virus. Thus, the previously observed 100%mortality in naïve (negative for antibodies
to CSFV) piglets infected with CSFV Koslov was reduced in the control piglets of this study to 30% for
challenge at the age of 7weeks and 50% at the age of 10weeks, respectively.
In conclusion, CP7 E2alf proved to be effective in preventingmortality, severe clinical signs and patho-
logical lesions in 5 or 8weeks old piglets positive for maternal antibodies derived from sows vaccinated
intramuscularly 4weeks before farrowing with one dose of C-strain vaccine.
© 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Classical swine fever is a highly contagious, often fatal disease
in pigs that can have tremendous socio-economic impact. The
causative agent, Classical swine fever virus (CSFV), belongs to the
genus Pestivirus of the family Flaviviridae [1]. It is an enveloped
RNA virus closely related to Bovine viral diarrhea virus (BVDV)
and Border disease virus (BDV) [2]. In the European Union (EU),
outbreaks of classical swine fever (CSF) are controlled by strict san-
itary measures [3]. Prophylactic vaccination is banned since 1990,
but legal provision is laid for emergency vaccination under certain
∗ Corresponding author. Tel.: +45 35 88 79 93; fax: +45 35 88 79 01.
E-mail address: asut@vet.dtu.dk (Å. Uttenthal).
circumstances [4]. Discussion regarding this alternative control
strategy was recently intensiﬁed both for domestic pigs and wild
boar [5]. At present, only conventional modiﬁed live attenuated
vaccines are used for routine vaccination in some countries out-
side of the EU, and in the EU as an emergency bait vaccination
of affected wild boar populations. Although efﬁcacious and safe,
these vaccines do not offer the possibility to detect infection in
vaccinated pigs [6] or to prove that antibodies are derived from
vaccination only. The inability of a country to prove the CSF-free
status by serosurveillance due to vaccination with live attenuated
vaccines, leads to restriction in the pig export [7]. To overcome this
problem, efﬁcacious and safe marker vaccines with accompanying
sensitive and speciﬁc diagnostic tests are needed. Two subunit
marker vaccines based on baculovirus expression of the CSFV
E2-glycoprotein have been registered of which only one is still
0264-410X/$ – see front matter © 2012 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.vaccine.2012.08.035
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available. Subunit vaccines can be used for prophylactic vacci-
nation; however they have a restricted use due to the following
reasons: repeated administration is needed to induce protection
and they are not applicable for oral vaccination [8]. In 2004, a new
chimeric marker vaccine candidate, “CP7 E2alf” was published
[9]. The vaccine candidate is based on a backbone of BVDV strain
“CP7” in which the E2 protein encoding sequence was replaced
by the corresponding region of the CSFV strain “Alfort187”. This
new vaccine proved in several studies to be efﬁcacious, safe and
applicable for oral administration [10–12]. However, all of the
present experiments were conducted in naïve pigs. In practice,
therewill be scenarioswith previous vaccination using live attenu-
ated vaccines; this may lead to the use of CP7 E2alf in animals that
possess maternally derived antibodies (MDA) against CSFV. Old
studies reported that the most effective time point for vaccination
of domestic piglets with MDA is from 5 to 8weeks of age [13]. For
this reason, a studywas conducted to deﬁne the optimal time point
for protective vaccination using “CP7 E2alf” in domestic piglets
with MDA obtained from C-strain vaccination of their mothers.
2. Materials and methods
2.1. Animals and vaccination trials
Four pregnant sows were purchased at approximately 86days
of gestation from a commercial Danish farm. The sows were
tested negative for CSFV and BVDV. Four weeks before farrowing
the sows were vaccinated intramuscularly using live attenu-
ated Riemser® C-strain vaccine (Riemser Schweinepestvakzine,
Riemser Arzneimittel AG, Germany) according to the manufac-
turer’s instructions.At farrowingpigletswerenumberedas follows:
sow A piglets 1–14; sow B piglets 21–33; sow C piglets 41–57; sow
D piglets 61–76. During the ﬁrst two weeks, eleven piglets were
excluded fromthe studydue togeneral healthproblems.At 4weeks
of age, the piglets were divided into four groups representing off-
spring of each sow. Group V5 included 13 piglets, while groups V8,
C5 and C8 included 12 piglets.
The CP7 E2alf pilot vaccine used for vaccination of the piglets
was produced by Pﬁzer Olot S.L.U (Spain). The vaccine was diluted
in sterile solution prior to administration based on pre-existing
potency data [14].
Animals of groups V5 and V8 were intramuscularly vaccinated
with 1ml of CP7 E2alf at 5 and 8weeks of age, respectively. Control
groups C5 and C8 received 1ml of vaccine diluent at the same time
points. All animals were challenged two weeks after treatment.
The four groups were kept in separate high-containment units and
observed daily for symptoms associated with CSF for a period of
2weeks post challenge. At the end of this period, the animals were
euthanized and pathological examinationswere performed. Piglets
that developed severe symptoms associated with CSF before the
end of the 2weeks were euthanized due to welfare reasons.
Theexperimentwas conducted in theanimal facilities at Techni-
cal University of Denmark, National Veterinary Institute, Lindholm
Denmark (DTU-Vet) in accordance with the requirements of the
DanishAnimal Experiments Inspectorate (License2008/561-1540).
2.2. Virus
The challenge virus (highly virulent CSFV strain “Koslov”) was
provided by the Friedrich-Loefﬂer-Institute (FLI, Germany). The
challenge material was diluted with Phosphate buffered saline
(PBS) to the theoretical titer (obtained from previous experiments)
of 105.5 TCID50 perml [14]. After back titrations, the virus had a titer
of 105.9 TCID50 per ml for the ﬁrst challenge trial of groups V5 and
C5 and 106.8 TCID50 per ml for the second challenge trial of group
V8 and C8, respectively. The challenge material was administered
intranasally at a dose of 2ml per piglet.
2.3. Sample collection
EDTA blood and serum samples were collected from the sows
on days 0 and 14 post vaccination, at farrowing, 2weeks post far-
rowing, and at the day of euthanasia. Piglets were sampled prior to
uptake of colostrum and once a week until vaccination. For practi-
cability reasons, the piglets with even and uneven numbers were
blood sampled at different days of the week. After vaccination,
blood samples were collected twice a week from all piglets. At
euthanasia, tonsils, spleen, kidney and mesenterial lymph nodes
were collected. All samples were stored at −40 ◦C until analysis.
2.4. Clinical examination
Following challenge, clinical signs were recorded daily accord-
ing to the protocol by Mittelholzer et al. [15]. Cumulative clinical
scores (CS)were calculated over time for individual pigs and for the
respective groups. In addition, rectal body temperature was mea-
sured on a daily base from 2days before vaccination until 14days
post challenge (dpc). A body temperature of >40.0 ◦C for at least
two consecutive days was recorded as fever.
2.5. Sample analysis
Total white blood cell (WBC) counts were carried out on
EDTA blood using a semi-automated Animal Blood Counter (Vet
abcTM, ABX, Montpellier, France). Physiological reference values
were deﬁned as follows: WBC 10–22×106 ml−1 and platelets
200–800×106 ml−1.
CSFV was isolated from tissue homogenates on PK-15 cells as
previously described [16], titrations were performed on triplicates.
The serum samples were tested for the presence of CSFV anti-
bodies by an in-house blocking ELISA [17].
Detection of viral RNA was performed on serum samples using
the CP7 E2alf and CSFV speciﬁc real-time reverse transcription
polymerase chain reaction (RT-qPCR) assays described by Ras-
mussenet al. [18] afterRNAextractionusing theQIAampRNABlood
mini kit (Qiagen).
2.6. Statistical analysis
Statistical analysis was performed using GraphPad in Stat ver-
sion 3.00 (GraphPad Software, San Diego, CA). Student’s t-test was
used to examine the signiﬁcance of differences between vaccinated
and mock-vaccinated control groups when it was relevant. Differ-
ences were considered statistically signiﬁcant with a probability of
p≤0.05.
3. Results
3.1. Clinical, hematological and pathological ﬁndings
3.1.1. Vaccination at 5weeks of age and challenge at 7weeks of
age
Following vaccination, neither fever nor other side effects were
observed in the piglets vaccinated at 5weeks of age (group V5).
Upon challenge infection, none of the piglets developed severe CSF
symptoms, but slight depression, increased temperatures (Fig. 1a)
as well as transient WBC and platelet count decreases were
observed around 3dpc in almost all animals of group V5 (Fig. 2a).
From 6dpc onwards, all piglets had physiological temperatures
again, but four piglets remained depressed.
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Fig. 1. Development of body temperature in: (a) vaccinated at 5weeks of age and challenged at 7weeks of age V5 (–) and control mock-vaccinated at 5weeks of age and
challenged at 7weeks of age C5 ( ) and in (b) vaccinated at 8weeks of age and challenged at 10weeks of age V8 (–) and control mock-vaccinated at 8weeks of age and
challenged at 10weeks of age C8 ( ). Each symbol represents the mean± SD. The signiﬁcant difference in the body temperatures between vaccinated and control groups
were indicated with *p<0.01; **p<0.001; ***p<0.0001.
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Fig. 2. Total white blood cell (WBC) counts in: (a) vaccinated at 5weeks of age piglets and challenged at 7weeks of age V5 (–) and controls C5 mock-vaccinated at 5weeks
of age and challenged at 7weeks of age ( ) and in (b) vaccinated at 8weeks of age and challenged at 10weeks of age V8 (–) and controls mock-vaccinated at 8weeks of
age and challenged at 10weeks of age C8 ( ). Each symbol represents the mean± SD.
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Fig. 3. Clinical scores (CS) recorded post challenge. CS in (a) vaccinated at 5weeks of age and challenged at 7weeks of age V5 (–) and control mock-vaccinated at 5weeks of
age and challenged at 7weeks of age C5 ( ), and in (b) vaccinated at 8weeks of age and challenged at 10weeks of age V8 (–) and control mock-vaccinated and challenged
at 10weeks of age C8 ( ). Each symbol represents the mean± SD. The † symbol stands for euthanasia and the clinical scores obtained from the euthanized animals at the
euthanization day are included in the data for the indicated time point.
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Table 1
Results obtained from control Group C5 (mock-vaccinated at 5weeks of age and challenged at 7weeks of age) and control Group C8 (mock-vaccinated at 8weeks of age and
challenged at 10weeks of age) at euthanization. Earlier days of euthanization and positive results for virus isolations are indicated in bold.
Group Pig # Euthanization day Body temperature
at euthanization
Clinical scores at
euthanization
Virus isolation
from tonsils
WBC (×106 ml−1)
at euthanization
Platelets
(×106 ml−1) at
euthanization
RNA viral load in
serum (Ct value)
C5 3 14 39.0 0 Positive 19.6 808 Negative
7 14 38.6 0 Positive 13.6 375 Negative
13 14 37.8 0 Positive 10.5 385 Negative
24 14 39.0 2 Positive 2.3 62 Ct 37
29 11 38.9 8 Negative 20 654 Negative
33 11 38.3 7 Negative 6.5 173 Negative
46 14 38.3 0 Positive 19.5 860 Negative
50 14 39.6 0 Positive 14.8 819 Ct 45
56 10 39.6 8 Positive 8.3 91 Ct 47
64 14 37.8 0 Positive 19.4 747 Negative
69 10 40.8 13 Negative 3.7 37 Ct 35
74 14 37.6 0 Positive 12.9 472 Negative
C8 4 14 39.2 3 Negative 10.6 573 Negative
9 14 39.1 1 Negative 18 804 Negative
14 7 40.9 14 Positive 6.6 79 Ct 24
25 14 38.5 1 Negative 14 536 Negative
30 7 41.6 12 Positive 4.4 127 Ct 22
41 11 38.3 12 Negative 6.4 170 Negative
47 14 39.1 1 Negative 10.5 319 Negative
52 14 38.8 1 Negative 12 750 Negative
61 14 38.8 3 Negative 12.5 657 Negative
65 10 40.6 9 Positive 6.4 28 Ct 27
71 11 39.9 9 Negative 4 39 Ct 36
76 9 41.2 9 Positive 3 103 Ct 27
In contrast, several mock-vaccinated piglets developed fever
(Fig. 1), leucopenia (Fig. 2) and severe clinical symptoms includ-
ing diarrhea, ataxia, and convulsions (Fig. 3). Four piglets of this
group had to be euthanized prior to the end of the trial (Table 1).
3.1.2. Vaccination at 8weeks of age and challenge at 10weeks of
age
The vaccinated piglets from group V8 did not exhibit adverse
reactions post vaccination. On day 3pc three piglets from group V8
had elevated temperatures and slight transient decreases of their
WBC counts. Similarly to group V5, on day 6pc all of the piglets
were back to normal. Slight depression and reduced appetite was
observed in two piglets on day 4pc. These mild symptoms were
observed up to day 10pc. None of the piglets from group V8 dis-
played signs of disease during the last four days of the experiment.
The mock-vaccinated piglets from group C8 were severely
affected post challenge and six piglets were euthanized before the
termination of the experiment. Fever started from day 2pc and 6
piglets had to be euthanized day 7–11pc (Table 1). The maximum
mean CS of 9 was reached at day 7pc (Fig. 3b).
While none of the vaccinated piglets showed thrombocytopenia
throughout the trial, all but one of the animals that had to be
euthanized prior to the end of the trial showed marked reduction
of platelet counts (Table 1). Over time, cumulative CS of 120, 18,
488 and 567 were calculated for groups V5, V8, C5 (challenged at
7weeksof age) andC8 (challengedat 10weeksof age), respectively,
showing that the control piglets challenged at 10weeks of agewere
most severely affected.
The postmortem examination of the two vaccinated groups (V5
and V8) revealed no pathological changes associated with CSF. In
contrast, typical lesions for CSF such as; petechiae in the tonsils,
spleen and kidney, and hyperemia in the mesenterial lymph nodes
were observed in seven piglets from C5 and eight piglets from C8,
respectively.
3.2. Antibody detection
At farrowing, all sows were tested positive for CSFV antibod-
ies (Fig. 4). The piglets that were blood sampled prior to uptake
of colostrum were CSFV antibodies negative. At the next sampling
3days later, all piglets were seropositive. Antibody decrease was
detected until challenge in all groups and around week 5 of age
the antibody levels fell below the threshold. After challenge the
antibody levels increased in the vaccinated piglets whereas the
antibody levels of the mock-vaccinated piglets remained close to
threshold.
3.3. Virus isolation from tonsils
In the control groups, infectious viruswas isolated from the ton-
sils of nine piglets from control group C5 and four piglets from
control group C8 (Table 1). No CSFV was isolated from the tonsils
of the vaccinated piglets.
3.4. Viral RNA detection in serum
Based on the RT-qPCR, viral BVDV RNA could not be detected in
the vaccinated piglets (data not shown). On day 3pc, a lowCSF viral
loadofmeancycle threshold (Ct) 36wasdetected in the serumsam-
ples from all piglets in both vaccinated groups V5 and V8 (Table 2).
Table 2
Virus RNA detection by RT-qPCR using CSFV probe in serum samples collected post challenge. The Ct values are expressed as the mean of all positive animals.
Group 3dpc 7dpc 10dpc 14dpc
V5 (vaccinated at 5 and challenged at 7weeks of age) 13/13 Ct 36 7/13 Ct 40 1/13 Ct 38 1/13 Ct 38
C5 (mock-vaccinated at 5 and challenged at 7weeks of age) 12/12 Ct 35 12/12 Ct 36 4/12 Ct 39 2/8 Ct 41
V8 (vaccinated at 8 and challenged at 10weeks of age) 12/12 Ct 36 3/12 Ct 36 2/12 Ct 40 1/12 Ct 43
C8 (mock-vaccinated at 8 and challenged at 10weeks of age) 12/12 Ct 35 12/12 Ct 30 4/9 Ct 38 0/6
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Fig. 4. Results obtained by blocking ELISA and depicted as average optical density (OD) %with a cut-off value of 70 (dashed line). Results≥70 are negative for CSFV antibodies
and results <70 are positive for CSFV antibodies. Graph (a) shows vaccinated at 5weeks of age and challenged at 7weeks of age V5 (–), control mock-vaccinated at 5weeks
of age and challenged at 7weeks of age C5 ( ) and sows at farrowing (). Graph (b) shows vaccinated at 8weeks of age and challenged at 10weeks of age V8 (–) and
control mock-vaccinated at 8weeks of age and challenged at 10weeks of age C8 ( ). Each symbol represents the mean± SD. The signiﬁcant difference in the OD% between
vaccinated and control groups were indicated with *p<0.01; **p<0.001; ***p<0.0001.
On day 7pc viral RNA was detected in the serum samples of seven
piglets from group V5 with a mean Ct of 40, and in three piglets
from group V8 with a mean Ct of 36. At day 14pc, only one pig in
both groups V5 and V8 was tested positive for CSF RNA.
Viral RNAwas detected in the serum samples of all piglets from
the control groups C5 and C8 on day 3 and 7pc. Two of the eight
remaining pigs from group C5 were tested positive with very low
viral load of 41 at day 14pc. No viral RNA was detected in the
remaining piglets from group C8 at the end of the experiment.
4. Discussion
The economy of many countries depends on the export of pigs
and pig products, and free trade relies on guarantees based on sero-
surveillance. Therefore, development of a marker vaccine that will
allow the detection of infection in vaccinated pigs is of paramount
importance. In several comparative studies the chimeric vaccine
“CP7 E2alf” was chosen as the ﬁnalmarker candidate to be brought
to registration [19]. Theefﬁcacyof this vaccinecandidatewas tested
only in naïve animals. However, the humoral immunity in endemic
areas will be based on MDA, thus we analyzed the efﬁcacy of a live
chimeric marker vaccine “CP7 E2alf” in piglets from C-strain vacci-
nated sowswhen the piglets were 5 or 8weeks old. The outcome of
challenge infection with highly virulent CSFV strain “Koslov” was
compared at an age of 7 and 10weeks with and without a prior
CP7 E2alf vaccination.
The maternal immunity was transferred very efﬁciently as all
piglets after colostrums ingestion were antibody positive at a
level close to what was seen for the sows. Following vaccina-
tion an increase in the antibody levels at 2weeks post vaccination
coincided with the time of challenge. The signiﬁcant difference
observed post vaccination between the antibody levels of the vac-
cinated and the mock-vaccinated animals showed that the MDA at
5 or 8weeks of age did not neutralize the vaccine virus. The experi-
ment used piglets from domestic sows. In wild boar population the
MDA level is expected to be higher [20] as sows give birth to fewer
piglets and there is a repeated vaccination in a presence of acute
infection. Thus, the outcome of vaccination with CP7 E2alf in wild
boar piglets might be different.
Challenge of unprotected piglets at 7weeks of age with highly
virulent CSFV strain “Koslov” is expected to result in high virus
levels in serum, severe disease, and almost 100% mortality within
2weeks [21]. In this study, both vaccinated and mock-vaccinated
piglets reacted with an increased body temperature. The mock-
vaccinated pigs had increased CS, and low CSFV RNA loads
corresponding to viral loads detected after infection with moder-
ately or low virulent strains were detected in the sera of all tested
animals at days 3 and 7pc. The course of the infection was very
mild compared to earlier studies in naïve piglets and the percent
of mortality decreased from 100% [22] to 50% when the piglets
were challenged at 10weeks of age and to 30% when challenged at
7weeks of age, respectively. Based on the back titrations a higher
doseof infectiousmaterialwasused for groupC8/V8 than forC5/V5.
This is considered to be of minor importance, as the titer of the
infectious material used for both challenge trials were higher than
the titer reported to cause 100% mortality [22].
According toMittelholzer et al. [15], CSs and body temperatures
of highly virulent CSFVs are deﬁned as: CS >15 and fever >41.0 ◦C.
Although 10 control piglets in our study were severely affected
and succumbed to the infection only one pig reached CS of 14 and
temperature rarely exceeded 41.0 ◦C. Similar tendency ofmortality
with low CS were observed in pigs challenged with highly virulent
strain “Margarita” that also belongs to genotype 1 [23]. Possibly,
the parameters used in the present study will be more precise for
strains of genotype 2.3 that show a prolong disease course with
multisystemic signs.
A decrease in the platelets was observed at day 3pc, and
severe depletion (below 100×106 cellsml−1) in this population
was observed fromday 7pc,which is later thanpreviously reported
in naïve animals [24]. With the exception of one piglet that
was euthanized with mild clinical signs, thrombocytopenia was
observed only in the piglets that were euthanized earlier with
severe clinical signs. This is in correlation with previous ﬁnd-
ings that thrombocytopenia is not a characteristic hematological
parameter in piglets with mild CSF [25].
Interestingly, many control piglets survived after challenge and
seemed to recover from infection. According to the planning all
piglets were euthanized 2weeks after challenge, so true recovery
could not be shown. Decreases in the CS in both control groups
were observed from day 7pc. Normal level of theWBC at day 14pc
was detected in all except one pig. No fever was recorded in these
pigs at the end of the experiment. The more severe clinical picture
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and the higher fatality in the piglets challenged at 10weeks of age
compared to the piglets challenged at 7weeks of age was probably
due to the lower level of MDA in these piglets.
The higher MDA level in group C5 represents a possible expla-
nation for the contrasting results obtained by virus isolation from
the tonsils of the piglets from this group. Although, CSFV was iso-
lated from the tonsils of all of the remained eight mock-vaccinated
piglets of group C5 no clinical signs were shown by these piglets
at the end of the experiment. Oppositely, three of the four piglets
euthanized earlier with high CS were tested negative for virus iso-
lation from their tonsils. No correlation was found between virus
isolation from tonsils and detection of viral genome in the serum
of these piglets. In group C8, viral genome in serum and infectious
virus in the tonsils was detected in the earlier euthanized piglets
only. Probably, the MDA in group C5 neutralized the virus and pre-
vented spreading. These pigletsmay become severely affected later
when theMDAdecrease andmayhave experienced a chronic infec-
tion. These ﬁndings support that the immune status contribute
signiﬁcantly to the clinical course of CSF [26].
Hyperthermia was observed in several animals in both vacci-
nated groups, but they were not accompanied by clinical signs
other than slight depression and lack of appetite. The mild clini-
cal picture correlated with the negative virus isolation from tonsils
and the lack of pathological lesions in the vaccinated piglets. Pos-
sibility for transmission of the challenge virus from the vaccinated
piglets seemed negligible as very low quantities of viral genome
were detected at day 3pc. In the vaccinated groups the number of
positive tested pigs decreased at day 7 and at day 14pc only two
vaccinated piglets remained positive.
The higher cumulative CS for group V5 compared to group
V8 was due to the more frequently observed depression. Porcine
immune system is fully matured at the age of four weeks [27],
less than ﬁve weeks of age thematernal immunity will protect and
interfere with vaccination [13].
5. Conclusions
CP7 E2alf proved to be effective in 5 and 8weeks old piglets
with MDA from sows vaccinated once intramuscularly with C-
strain 4weeks before farrowing. The vaccine prevented mortality,
severe clinical signs and pathological lesions when the piglets
were challenged with highly virulent CSFV strain, two weeks post
vaccination. Although maternal immunity in some of the mock-
vaccinated piglets proved to be sufﬁcient to prevent mortality it
did not adversely affect the successful vaccination with CP7 E2alf.
The vaccine was safe in piglets of 5 and 8weeks of age positive for
C-strain MDA as no side effects or fever was observed post vac-
cination. When comparing the efﬁcacy of CP7 E2alf in 5 and in
8weeks-of-age piglets no major differences were found. Consid-
ering the remarkable protection by the maternal immunity up to
7weeks-of-age it is advised to vaccinate domestic piglets in C-
strain vaccinated areas at 5weeks of age.
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Abstract 
Implementation of vaccination in emergency situation with marker vaccine against Classical Swine 
Fever (CSF) together with a sensitive and specific discriminatory test will give the possibility of 
tracing residual infections and ease the pig trade restrictions. CP7_E2alf is a promising CSF live 
chimeric marker vaccine candidate that use as a backbone Bovine Viral Diarrhea Virus (BVDV) in 
which E2 protein is replaced by E2 protein of Classical Swine Fever Virus (CSFV). The present 
study aimed to evaluate the differentiation of infection in vaccinated animals (DIVA) potential of 
CP7_E2alf in piglets from sows vaccinated once intramuscularly with live attenuated C-strain 
vaccine. At 5 or 8 weeks of age these piglets were vaccinated intramuscularly with CP7_E2alf. 
After two weeks the vaccinated piglets and their mock-vaccinated controls were challenged and 
euthanized 14 days later. Five piglets from each group and each sow were analyzed.  
Both Erns and E2 specific antibodies were transferred with colostrums. Priocheck® CSFV Erns 
ELISA detected maternal Erns antibodies up to 4 weeks of age only in 7 out of 18 tested piglets. As 
expected, after vaccination until challenge no Erns specific antibodies were detected. All 20 
challenged piglets, except one vaccinated at 8 weeks of age, seroconverted to Erns at day 10 post 
challenge. In conclusion, the new marker candidate CP7_E2alf could be applied as a DIVA vaccine 
in piglets positive for C-strain maternal antibodies when the piglets are vaccinated intramuscularly 
at 5 or 8 weeks of age.   
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1.Introduction 
Classical Swine Fever Virus (CSFV) is a positive stranded enveloped RNA virus that together with 
Bovine Viral Diarrhea Virus (BVDV) and Border Disease Virus (BDV) belongs to the genus 
Pestivirus within the family Flaviviridae [1]. Outbreaks of CSF in the European Union (EU) 
countries with an industrialized pig production result in enormous economic losses due to the 
current control strategy including culling of infected animals. An alternative to this strategy is an 
emergency vaccination. However, live attenuated vaccines that are used until present do not allow a 
differentiation of infection in vaccinated animal (DIVA) [2]. A novel efficacious and safe marker 
vaccine that follows the DIVA concept may overcome this problem. Accompanying DIVA test that 
detects infected pigs in a vaccinated population will allow declaring infection free status and 
shortening of the export restriction period. Therefore, without reliable sensitive and specific 
discriminatory test marker vaccines will not be applicable during an emergency field situation. CSF 
humoral immunity relays mainly on antibodies directed against E2 and Erns nonstructural proteins 
[3]. Based on these characteristics a marker vaccine candidate “CP7_E2alf” was constructed [4]. 
Here, E2 protein encoding sequence in this vaccine was deleted in BVDV strain “CP7”backbone 
and replaced by the same protein of the CSFV strain “Alfort187”. The corresponding discriminatory 
ELISA test detects antibodies specific against the CSFV Erns glycoprotein and antibody positive 
pigs are regarded as CSFV infected. Problems might appear when this discriminatory test is 
implemented in population previously vaccinated with conventional live attenuated vaccines. 
Firstly, Erns antibodies could be passively transferred from mothers to their piglets that will be tested 
positive in absence of infection. Secondly, maternal antibodies (MA) may neutralize even highly 
virulent CSFV as previously described [5]. Uptake of MAs might prevent induction of active 
antibodies against Erns protein, later, when the MAs decrease, no specific Erns antibodies will be 
produced. Additionally the delayed humoral immunity may also impair Erns response post CSFV 
infection [6].  
These scenarios are possible in European endemic areas where C-strain vaccine baits oral 
vaccination is used for wild boar in case of outbreak [7]. Some EU candidate countries currently use 
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conventional vaccination with local live attenuated vaccine variants, but would like to cease 
vaccination as soon as possible [8]. For these countries an intermediate step could be 
implementation of vaccination with CP7_E2alf. Therefore, MA due to the practice of routine 
vaccination to prevent circulation of CSFV might interfere with the sensitivity of the discriminatory 
ELISA test [9]. 
Thus, the present study evaluated the DIVA potential of CP7_E2alf in piglets with C-strain 
maternal antibodies that were vaccinated at 5 or 8 weeks of age. The DIVA concept that implies the 
possibility to detect infected animals within a vaccinated population was tested when the piglets 
were infected two weeks post vaccination.  
 
2. Materials and methods 
2.1. Animals trials, sample collection and clinical examination 
Animal trial, sample procedure and clinical examination were performed as described previously 
[5]. Briefly, pregnant sows were vaccinated intramuscularly with one dose of live attenuated C-
strain vaccine four weeks before farrowing. At 4 weeks of age, the piglets were weaned and divided 
into four groups representing offspring of each sow. Group V5 and V8 were vaccinated 
intramuscularly with 1ml of CP7_E2alf at age of 5 or 8 weeks, respectively. The control groups C5 
and C8 were mock-vaccinated at the same time points as their corresponding groups. All groups 
were challenged with highly virulent strain “Koslov” two weeks post vaccination and euthanized 14 
days post challenge.  
Serum samples were obtained from the four sows before vaccination, at day 14 post vaccination, at 
farrowing, 14 days post farrowing and at euthanization. Five piglets were analyzed from each 
group, they were sampled prior to uptake of colostrums and once a week until vaccination. Post 
vaccination the blood samples were collected twice a week to be tested for development of 
neutralization antibodies, E2 and Erns   specific antibodies.  
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2.2. Antibody analyses 
Serum samples were examined for neutralizing antibodies to CSFV through a direct virus 
neutralization peroxidise-linked assay (NPLA) [10], with some modifications. In brief, two fold 
dilutions in triplicate of heat - inactivated serum starting from 1:10 were incubated for 1hour against 
100 infective units homologous C-strain vaccine virus (for the samples obtained from vaccinated 
and mock-vaccinated piglets) or the reference CSFV Alfort 187 strain (for the samples obtained 
from vaccinated piglets only). To increase the titer of the C-strain vaccine virus the virus was 
propagated four times in SFT cells. After incubation, PK-15 cells were added and the plates were 
incubated 3 days. The cell-monolayers were fixed and stained as previously described [11] and viral 
titers were calculated [12].  
Detection of viral RNA was performed on serum samples using the CP7_E2alf and CSFV specific 
real-time reverse transcription polymerase chain reaction (RT-qPCR) assays [13] after RNA 
extraction using the QIAamp RNA Blood mini kit (Qiagen).  
The presence of CSFV E2-specific antibodies was tested using HerdChek® CSFV Ab ELISA 
(IDEXX Laboratories, Hoofddorp, The Netherlands). Priocheck® CSFV Erns ELISA kits were 
kindly provided by Prionics Lelystad BV, Lelystad, The Netherlands. Both tests were performed 
according to the manufacturer’s instructions.  
2.3 Statistical analysis 
Statistical tests were performed using GraphPad in Stat version 3.00 (GraphPad Software, San 
Diego, CA). Student’s t-test was used to examine the significance of differences between 
vaccinated and mock-vaccinated control groups when it was relevant. Differences were considered 
statistically significant with a probability of p ≤ 0.05 (statistical significance is indicated in the 
figures). 
3. Results 
3.1. Kinetics of maternal immunity 
The sows were tested positive for neutralizing antibodies two weeks post vaccination but no viral 
genome was detected at this time point. At farrowing the mean antibody titer was 195 and the 
 
 
 
 
 
 
55 
 
similar titer of 145 was detected in the one-week-old piglets after ingestion of colosrum (Fig.1). 
Before uptake of colostrum all piglets were antibody negative in all tests. The neutralization 
antibody titer of the sows was increasing up to euthanization. From week 2 of age the neutralization 
antibody titers of the piglets decreased and at 5 weeks of age all piglets had titer below 64. At 10 
weeks of age 4 piglets still tested positive in very low titers. At farrowing, all four sows were 
seroconverted to E2-specific antibodies. Stable increase in the percentages of inhibition values in 
the four sows were observed from day 49 post vaccination until euthanization. No clear CSFV Erns 
specific antibody response was detected in the sows post C-strain vaccination; however, at 
farrowing and 14 days later, two of the sows had an increased inhibition percent close to threshold. 
In the piglets, neither Erns nor E2 specific antibodies were detected prior to uptake of colostrum 
(Fig.2). After ingestion of colostrum, week one 4 out of 18 tested piglets were positive for Erns 
specific antibodies and at week 4 the positive piglets were only two. From week 5 of age until week 
3 post vaccination all piglets remained Erns antibody negative. E2 specific antibodies were detected 
in all of the tested piglets after uptake of colostrum and these antibodies were present in 2 out of 20 
piglets up to six weeks of age. 
3.2. Neutralization response post vaccination and challenge 
Neutralization antibody response to vaccination in the piglets vaccinated at 5 weeks of age (V5) 
was first detected at day 14 post vaccination (Fig.3 a). The piglets vaccinated at 8 weeks of age 
(V8) had the highest titer of neutralizing antibodies post vaccination (Fig.3 b). The antibody levels 
in group V8 increased from day 7 after vaccination. Slightly higher antibody titers against CSF 
strain Alfort than against C-strain vaccine virus were detected for both groups V5 and V8, 
respectively.  
Increase in the neutralization antibody titer was detected 7 days post challenge in the remaining 
piglets from group C5 only (Fig.3 a). No increase in the antibody response was detected in the 
remaining piglets from group C8 until the termination of the experiment (Fig.3 b).  
3.3. DIVA potential in piglets with maternal C-strain antibodies 
At the time of vaccination the youngest piglets (V5 and C5) had, as expected, higher levels of E2 
antibodies than those vaccinated at 8 weeks (V8 and C8). After vaccination a significant difference 
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in the E2 specific response between vaccinated and mock-vaccinated piglets occurred. Both 
vaccinated groups seroconverted at day 21 post vaccination whereas only one mock-vaccinated pig 
was tested positive at euthanization (Fig.4 a & b). 
The first post vaccination response to CSFV specific Erns antibodies appeared at day 3 post 
challenge in one piglet from group V8. With the exception of one pig from group V8 all vaccinated 
and mock-vaccinated piglets had seroconverted to Erns at day 10 post challenge (Fig. 5 a & b).  
4. Discussion 
CP7_E2alf vaccine proved to be efficacious and safe [14], but without a specific and sensitive 
accompanying discriminatory tool it would be not feasible as a DIVA vaccine. Priocheck® CSFV 
Erns ELISA is the only commercially available test that is specific for CSF and is suitable as 
discriminatory tool after vaccination with CP7_E2alf. In the present study, the DIVA potential of 
this ELISA test was evaluated in piglets with C-strain maternal antibodies vaccinated 
intramuscularly with CP7_E2alf at 5 or 8 weeks of age.  
Although, all tested piglets were positive for neutralizing antibodies at 5 weeks of age and 4 out of 
12 piglets still had MA at 10 weeks, no piglets were tested positive for CSFV specific Erns 
antibodies from 5 weeks of age up to challenge. Thus, no interference of maternal C-strain 
antibodies with the DIVA potential of CP7_E2alf in domestic piglets older than 4 weeks of age was 
observed.  
None of the vaccinated animals were positive for Erns CSFV specific antibodies prior challenge. 
Already at day 3 and 7 post challenge one and three piglets, respectively, were tested Erns positive. 
As antibody response to CSFV does not appear earlier than 7 days post infection and there was a 
significant difference between the vaccinated group V8 and the mock-vaccinated C8, we assume 
that the Erns positive results were boosted by a cross reactivity with the vaccine BVDV Erns 
proteins. As was mentioned above, the piglets of V8 had a lower MA levels at the time of 
vaccination than the piglets of V5 group and due to this also responded with a higher neutralization 
titer after vaccination. Erns proteins are highly conserved among Pestiviruses and correlation 
between false positive for Erns antibodies results and high neutralization antibody titer was 
previously reported [15]. In the present study the addition of a vaccinated-not-challenged group 
 
 
 
 
 
 
57 
 
would have been of use. Positive CSFV Erns results in this a group would confirm the cross 
reactivity to the vaccine BVDV Erns proteins. The recently published confirmatory ELISA test [15] 
might be also a solution in future analyses. 
According to the Diagnostic Manual [16], serum samples, obtained 21 days post infection, must be 
detected by ELISA tests. In the present study, all except one piglet from the vaccinated group V8 
seroconverted to Erns specific antibodies before day 10 post challenge. The piglet that did not 
seroconvert was euthanized as planned at the termination of the experiment on day 14 post 
challenge and it was not possible to prove later seroconversion.  
Interestingly, no correlation between the results obtained from the sows by neutralization test and 
Erns specific ELISA were observed. No clear Erns specific antibodies seroconversion was detected in 
the sows, but at farrowing, two sows showed an inhibition percent close to the cut off value of 40 % 
(29% and 35%). The piglets that tested Erns positive after uptake of colostrum were offspring of 
these sows. However, for all sows high levels of neutralizing antibodies and E2 antibodies were 
detected until euthanization. Previous study has also shown that vaccination with C-strain do not 
produce strong Erns ELISA antibodies [2, 17]. Possible difference between C-strain and CSFV 
genotype used for validation of these tests was proposed as an explanation. The very limited 
replication of C-strain vaccine virus might be another reason [6, 14, 18]. In the present study, no 
CSF viral genome was detected in serum samples obtained by the sows after vaccination.  
The correlation between the positive results obtained from the sows by NPLA and E2 specific 
ELISA supports the major role of E2 specific antibodies in the development of immunological 
response to CSF. Also after vaccination of the piglets, a clear increase of the neutralization 
antibodies and E2 inhibition percent was observed in the vaccinated piglets only. This confirmed 
that CP7_E2alf vaccine virus overcome the maternal C-strain antibodies and induced active 
immunity. As expected, these results consolidated the inability of NPLA to be applied as a 
confirmatory test after vaccination with CP7_E2alf, due to the CSFV E2 gene in this chimera [15].  
Because of the lower MA, the piglets vaccinated at 8 weeks of age responded earlier to challenge 
infection with higher neutralization titer than the piglets vaccinated at 5 weeks of age. Despite the 
fact that C-strain and strain Alfort used for the NPLA belong to genotype 1, higher neutralization 
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antibody titers after vaccination with CP7_E2alf were obtained when the test was performed against 
homologous strain Alfort.   
Although, there was no increase of the antibody titer in the mock-vaccinated group C8 and a slight 
increase in group C5, the mortality was significantly reduced in both groups. After challenge, the 
detected low titer in the survived mock-vaccinated piglets was able to protect them from the 
challenge infection with high dose of CSF virulent strain Koslov [5]. The results showed that a 
lower neutralization antibody titer than previously reported of ≥25 [19] resulted in adequate 
protection of some piglets. This finding is in agreement with previous study that revealed no 
relation of MA to survival [20] and suggests that besides humoral immunity, other individual 
complex mechanisms were involved.   
Conclusion 
In domestic pig populations previously vaccinated intramuscularly with C-strain vaccine a 
discriminatory test could be implemented as early as 5 weeks of age. No interference of maternal 
immunity with the DIVA potential of CP7_E2alf is expected when domestic piglets are vaccinated 
intramuscularly at the age of 5 or 8 weeks and challenged 2 weeks later.  
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Fig.1. Kinetics of CSF maternally derived C-strain antibodies tested in the piglets by neutralization test, 
mean values of 12 nonvaccinated piglets (group C8), the black symbols represents the mean antibody titers 
of the C-strain vaccinated mothers. Each symbol represents the mean ± SD. 
 
 
 
Fig.2. E2 and Erns specific maternal antibodies kinetics tested by blocking ELISA in piglets from C-strain 
vaccinated sows. The dashed line marks the cut-off. Each symbol represents the mean ± SD. 
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Fig.3. Neutralizing antibody response post vaccination against CSF C-strain vaccine virus (for the vaccinated 
pigs) or strain CSFV Alfort/187 (for both vaccinated and control pigs). Graph (a) shows group C5 and V5-
vaccinated at 5 weeks of age and challenged at 7 weeks of age. Graph (b) shows group C8 andV8-vaccinated 
at 8 weeks of age and challenged at 10 weeks of age. Each symbol represents the mean ± SD.  
 
 
 
   
 
Fig.4.Response to CSFV E2 specific antibodies in (a) group V5 (vaccinated at 5 weeks of age) and C5 
(mock-vaccinated at 5 weeks of age) and (b) group V8 ( vaccinated at 8 weeks of age) and C8 ( mock-
vaccinated at 8 weeks of age). The dashed line marks the positive and the doubtful results according to the 
manufacturer. Black arrows mark the challenge, 14 days after vaccination. Each symbol represents the mean 
± SD.  (***)values significantly different between groups with  p ≤ 0.001. 
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Fig.5. Response to CSFV  Erns specific antibodies in (a) group V5 (vaccinated at 5 weeks of age) and C5 
(mock-vaccinated at 5 weeks of age) and (b) group V8 ( vaccinated at 8 weeks of age) and C8 ( mock-
vaccinated at 8 weeks of age). The dashed line marks the cut-off. Black arrows mark the challenge infection 
time point. Each symbol represent the mean ± SD. (*)values significantly different between groups with p ≤ 
0.05. 
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Abstract  
Generally, humoral immunity has been accepted to be the major protective mechanism against 
classical swine fever (CSF). Recently, however the role of cellular immunity in the defense against 
this infection has been revealed as well. Evaluation of the predominant part of the immune system 
activated after vaccination will aid the development of more effective vaccines. In this experiment, 
we studied the kinetics and the modulation of the immune system in sows vaccinated 
intramuscularly with C-strain and in their piglets vaccinated with a new live marker vaccine 
CP7_E2alf. The piglets were vaccinated or mock-vaccinated intramuscularly at 5 or 8 weeks of age 
and challenged two weeks later.   
Bias towards IgG1 isotype antibodies over IgG2 suggests predominant activation of Th2 cells 
(humoral immunity) than Th1 cells (cellular immunity).Thus, we evaluated the induction of CSFV-
specific IgG1 and IgG2 responses and their relation to Th1 and Th2 cytokines (IL-4 and IFN-γ, 
respectively). Modulation of C-reactive acute phase protein (CRP) by CP7_E2alf vaccine was also 
investigated. C-strain vaccination of sows seems to activate predominantly the cellular immunity 
(Th1) that probably was transferred to the offspring and might be the reason for the reduced 
mortality in the mock-vaccinated control. Oppositely, the predominant elevation of IgG1 isotype 
specific antibodies following vaccination with CP7_E2alf indicates a possible activation of the 
humoral part of the immunity (Th2). No IL-4 was detected and a low concentration of IFN-γ was 
present in all groups except the vaccinated at 8 weeks of age V8. The lack of IFN-γ in the presence 
of high level of IgG1antibodies detected in V8 supports the hypothesis that intramuscular 
vaccination with CP7_E2alf activates mainly the humolar part of the immune system. The detected 
decrease in the CRP secretion by CP7_E2alf vaccine and the maternal immunity confirmed the 
possibility to utilize this protein as a tool for early prediction of CSF infection outcome.  
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1. Introduction 
Classical swine fever virus (CSFV) is a small enveloped positive-stranded RNA virus classified in 
the genus Pestiviruses family Flaviviridae [1]. It is one of the most important viral infectious 
diseases of domestic pigs as an outbreak leads to substantial economical losses as well as to culling 
of enormous number of completely healthy pigs [2]. Highly virulent strains of CSFV cause an acute 
form of the disease, characterized by high fever, hemorrhagic lesions and high mortality [3]. The 
virus can efficiently evade and compromise the host immune system, causing lymphoid organ 
atrophy, with thrombocytopenia, granulocytopenia, and severe lymphopenia, particularly in B cells, 
due to apoptosis [4]. Protection is mainly associated with the humoral immune response, but 
neutralizing antibodies to CSFV usually appear 2 weeks post vaccination [5]. Thus, it is suggested 
that mechanisms as cellular immunity are involved during the early protection [6]. Cell-mediated 
immunity (CMI) is known to have both an effector and regulatory role on the immune system and it 
is believed to be essential for immunity against intracellular pathogens, including viruses. 
Evaluation of specific cytokine release that is known to influence or directly relate to humoral or 
cellular immunity is a way to investigate the part of the immune response that is predominantly 
activated after vaccination or infection and is responsible for providing protection. The role of 
cytokines in regulation and modulation of the immune response has been widely studied since the 
Th1/Th2 paradigm was postulated. This paradigm suggests that after priming T helper cells are 
polarized in two distinct subsets (Th1 or Th2) that can be distinguished by their cytokine expression 
[7]. Thus, IL-12 and INF-γ (Type 1 cytokines) are considered to be key cytokines in Th1 profiles 
and serves as indicators of a predominance of cell-mediated responses, whereas IL-4 (Type 2 
cytokine) participates in Th2 polarization and dominance of humoral response [8]. In all animal 
species studied, immunoglobulin (Ig) G isotype expression is controlled by Type 1 and Type 2 
cytokines. In pigs, it was reported that a high IgG1:IgG2 ratio (IgG1>IgG2) was a response to Type 
2 (IL-4) cytokines and the inverse was to Type 1 (INF-γ) [9]. Recently, Graham et al. [10] proved 
the role of INF-γ response induced by intramuscular vaccination with the conventional live 
attenuated C-strain vaccine in early protection induced against CSFV challenge. Previously, 
Suradhat et al. [11] revealed that cellular immunity was also induced by C-strain vaccination in 
piglets from sows vaccinated with C-strain. Although, this vaccine is very effective and safe it is not 
possible to distinguish serologically between vaccinated and infected piglets [5]. The new marker 
candidate CP7_E2alf is a chimera vaccine that proved to be safe, efficacious and suitable as a 
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DIVA vaccine [12]. However, there is no knowledge about the modulations of the immune system 
by CP7_E2alf vaccination and consequent CSFV infection in piglets with maternal C-strain 
antibodies.  
The current experiment aimed to study the activation of early specific immunity induced against 
CSF, based on  IgG1 and IgG2 antibodies levels in piglets from C-strain vaccinated mothers, 
intramuscularly vaccinated at 5 or 8 weeks of age with the new CP7_E2alf marker vaccine and then 
challenged two weeks post vaccination.  The duration of maternal antibodies as well as their 
kinetics after vaccination with CP7_E2alf and consequent challenge was assessed. In order to 
support the predominance of one of the two parts of the specific immunity (humoral or cellular) 
post infection, the release of Type 1 (IFN-γ) and Type 2 (IL-4) cytokines was analyzed. 
Furthermore, to better understand the protective role of specific immunity in the piglets post 
infection, the release of C-reactive protein (CRP), as an indicator of CSFV infection outcome was 
studied as well.  
 
2. Materials and methods  
2.1. Animals trials, sample collection and clinical examination 
Animal trial, sample procedure and clinical examination were performed as described [13]. Briefly, 
the piglets of four sows vaccinated with C-strain vaccine were divided at 4 weeks of age into four 
groups. Group V5 and V8 were vaccinated intramuscularly at 5 or 8 weeks of age, respectively, 
with a new marker vaccine CP7_E2alf and their control groups C5 and C8 were mock-vaccinated. 
The piglets were challenged two weeks post vaccination, and euthanized 14 days post challenge. 
The groups were selected, so that piglets from all sows were represented in each group. From the 
two control mock-vaccinated groups were included piglets that developed severe clinical signs of 
CSF and were euthanized before the termination of the experiment. The piglets from the two 
vaccinated groups did not show clinical signs, so they were randomly selected. Serum samples from 
the four sows were tested at farrowing and at euthanization. Piglets were blood sampled prior to 
uptake of colostrums and once a week until vaccination. Post vaccination the blood samples were 
collected twice a week. 
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2.2. Sample analysis 
CSFV-specific IgG1and IgG2 antibodies were measured in serum by indirect ELISA as described 
before [14]. Briefly, CSFV infected cell extract, prepared using a detergent solution containing 2% 
Octyl beta, 1 D glucopyranoside (OGP), was applied to Nunc Maxisorp microplates overnight at 
room temperature and blocked for 1 h at room temperature with 10%  FBS-2% milk in Phosphate 
buffered saline (PBS). Thereafter, sera were incubated for 1 h at 37°C with either mouse anti-
porcine IgG1 antibody diluted at 1/250 (for detection of specific IgG1 antibodies) or mouse anti-
porcine IgG2 antibody diluted at 1/100. Anti-mouse IgG HRP-conjugated secondary antibody was 
added at a dilution of 1/250 (DAKO) for 30 min at 37°C and the peroxidase activity was measured 
using the TMB substrate (Sigma-Aldrich) at 450 nm. The values obtained for tested sera were 
compared to negative control and to high positive control sera from either unvaccinated or C-strain 
vaccinated piglets from unvaccinated sows. 
Furthermore, porcine cytokines were measured in serum post challenge using ELISA kits from 
Invitrogen (Life Technologies, Carlsbad, USA) for IFN-γ and IL-4 according to the manufacturer’s 
instructions and the concentrations in the sera were determined from a standard curve. The level of 
C-reactive protein (CRP) in serum obtained from the piglets post challenge was determined using 
an indirect ELISA as previously described [15].  
2.3 Statistical tests 
The variation for a vaccinated group compared to the respective control group was analyzed by 
Student’s t-test using GraphPad in Stat version 3.00 (GraphPad Software, San Diego, CA). 
Differences were considered statistically significant with a probability of p ≤ 0.05. 
3. Results 
3.1. Isotype specific antibody response post C-strain intramuscular vaccination in sows and 
evaluation of the longevity of these maternal antibodies in piglets 
Similar levels of IgG2 and IgG1 were detected in the four sows at 4 weeks post vaccination, but at 
euthanization IgG2 was the predominant isotype (Fig.1). In the piglets, both IgG1 and IgG2 CSF 
specific antibodies were present after uptake of colostrum (Fig.1). Higher levels of IgG2 than of 
IgG1 CSF specific maternal antibodies were detected during the tested period with both isotypes 
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peaking week 1 and declining untill 10 weeks. The ratio of IgG1 over IgG2 was calculated to obtain 
more precise information on the specific immunity as results < 1 indicate Th1 cellular immunity 
and results > 1 indicate Th2 humoral immunity. Early protection provided by maternal immunity in 
piglets from C-strain vaccinated mothers revealed to be mainly to Th1 cellular immunity as the 
IgG1/IgG2 ratio was calculated < 1(Fig. 1b). Similarly to the neutralizing antibodies (Manuscript 
2), the levels of the CSF specific IgG1 and IgG2 antibodies started to decrease from week 2 of age. 
3.2. Immune response modulation post CP7_E2alf intramuscular vaccination  
For both groups of unvaccinated piglets (C5 and C8), an increase of CSFV-specific antibody levels 
was not observed, neither for IgG1 nor IgG2, post-challenge (Fig.2). At 7 weeks or 10 weeks of 
age, when the challenge was administered, maternal isotype specific antibodies were detected at 
very low levels in piglets (Fig.1). However, a stimulation of IgG1 production was observed from 21 
dpv (i.e. 7 days post-challenge) for both groups of CP7_E2alf vaccinated piglets (V5 and V8) 
(Fig.2a). The strongest IgG1 response was detected in the piglets vaccinated at 8 weeks of age (V8). 
No significant IgG2 production was stimulated until the end of the experiment for both vaccinated 
groups (Fig.2b) 
No significant elevation of the IgG2 specific antibody levels was detected post vaccination in the 
four groups (Fig.2 b). The raise of IgG1 response started from day 21 post vaccination in the piglets 
from group V8 (vaccinated at 8 weeks of age) and group V5 (vaccinated at 5 weeks of age). In the 
two vaccinated groups, the IgG1 levels were increasing until the termination of the experiment. The 
strongest IgG1 response was detected in the piglets vaccinated at 8 weeks of age (V8). In contrast to 
the vaccinated groups, the IgG1 level in the mock-vaccinated piglets started to decrease from day 
17 post vaccination and continued until the end of the experiment (Fig. 2 a).  
Due to the single stimulation of IgG1 isotype induced by CP7_E2alf vaccination, the IgG1:IgG2 
ratio indicates a balance towards Th2 humoral response (Fig.2 c). However, no Il-4 was detected 
post challenge in any of the four groups (data not shown). Low concentrations of IFN-γ were found 
in a few piglets mainly from the mock-vaccinated group C5 (Fig.3). Two piglets from V5 and one 
piglet from C8 were tested positive for IFN-γ at day 3 and day 7 post challenge, respectively. This 
cytokine was not detected in the vaccinated at 8 weeks of age piglets.  
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The duration of CRP over-production induced by challenge infection was significantly reduced at 
day 10 post challenge in the vaccinated group V8 compared to the mock-vaccinated group C8 (Fig. 
4 b). At day 3 post challenge, the piglets vaccinated at 5 weeks of age had significantly higher 
concentration of CRP than their control mock-vaccinated group. The two groups (V5 and C5) did 
not have significantly different levels of CRP from day 7 post challenge until euthanization (Fig. 4 
a).  
4. Discussion 
The role of the cellular immunity in protection against CSF infection has been revealed [16,]. The 
early protection that this part of the immune system provides against CSFV is especially important 
in confining spread of the infection in situation of emergency. In the European Union, marker 
vaccines may be implemented in a case of outbreak, thus, the capacity of a new marker vaccine 
CP7_E2alf to polarize the adaptive immunity towards Th1or Th2 response is important to 
investigate.  
With the present study, we aimed to evaluate the polarization of the immune response against CSFV 
in positive for C-strain MDA piglets that were vaccinated with CP7_E2alf at 5 or 8 weeks of age 
and challenged 2 weeks later. Although, similar levels of IgG1 and IgG2 isotype antibodies were 
detected in the sows at farrowing, at the end of the experiment in the sows and after uptake of 
colostrums in the piglets the level of IgG2 was significantly higher than that of IgG1.The 
predominance of IgG2 isotype antibodies transferred to the piglets with colostrum is in agreement 
with the previously reported IgG2 concentration of up to 75% in young piglets [17]. The over-time 
elevation of IgG2 concentration detected in the sows suggests a long time activation of Th1 cells 
post C-strain vaccination. 
Oppositely to the predominant IgG2 elevation detected post administration of C-strain vaccine, the 
CP7_E2alf vaccination led to increase mainly of IgG1 isotype specific antibody levels. It can be 
argued that the observed difference in the outcome of the two vaccinations was due to challenge 
infection post CP7_E2alf vaccination. However, a possible influence of the challenge infection and 
the maternal immunity on the IgG1 response post CP7_E2alf vaccination might be excluded as a 
significant difference in the IgG1 levels was detected between the vaccinated and the mock-
vaccinated piglets.  
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Predominant activation of Th1 cells post C-strain vaccination and a possible consequent transfer 
with the colostrum mainly of maternal Th1 cells and probably the related cytokines might be the 
reason for the observed reduced mortality in presence of very low or insufficient levels of 
neutralization antibodies in the mock-vaccinated piglets (Manuscript 2). However, this theory has to 
be supported by further investigation of the colostrum’s components and the correlation between 
their presence in the piglets and the provided protection.  
IFN-γ appears to serve as a good marker for anti - CSFV cell mediated response and its relation to 
IgG2 production in pigs was proven [18, 19]. Thus, it was relevant with the present study to analyze 
IFN-γ release in piglets post challenge. No clear correlation was found between protection and 
detection of IFN-γ in serum samples from the mock-vaccinated piglets. IFN-γ in low concentration 
was present both in the surviving piglets and in the piglets that succumbed to the challenge 
infection. However, there was a correlation between virus replication or high virus levels and 
detection of IFN-γ in serum. CSFV was isolated from the tonsils of all mock-vaccinated piglets 
tested positive for IFN-γ (pig 3, 13 and 30) [13]. Virus genome was only detected at day 3 post 
challenge in the two piglets from V5 group that were tested positive for IFN-γ at the same time 
point. These results revealed that at an early time point, CSFV infection might enhance the 
induction of IFN-γ.  
The lack of IFN-γ secreted in serum samples obtained post challenge from the vaccinated at 8 
weeks of age piglets (V8) correlated with the absence of IgG2 antibody increase in these piglets 
during the same period and is probably due to the very fast activation of the humoral immunity. 
From the two vaccinated groups, the piglets of V8 responded earlier with higher levels of 
IgG1specific antibodies. Thus, the lack of IFN-γ in the presence of high level of IgG1antibodies 
indicates that intramuscular vaccination with CP7_E2alf activates mainly the humolar part of the 
immune system.   
As IL-4 is a type 2 cytokine that stimulates B cells activation and immunoglobulin - class 
switching, correlation of results obtained for this cytokine and the above presented findings could 
confirm the predominant activation of Th2 cells post CP7_E2alf intramuscular vaccination. 
However, the negative results obtained for secreted cytokine in presence of very clear antibody 
response [13], suggest as previously reported [8] a low sensitivity of the utilized ELISA test in 
serum samples. 
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The acute-phase response is an early nonspecific protective mechanism against pathogens that 
precedes the specific immune defense and declines shortly after removal of the triggering factor 
[20]. In pigs, CRP is considered a major acute-phase protein that quickly reacts and exhibits a 
moderate increase [15]. In the present study the level of CRP post challenge infection with highly 
virulent CSFV strain was generally lower than previously reported [21,  22]. The attenuation of the 
challenge virus by the maternal immunity as we reported previously [13] is a probable explanation 
for the reduced secretion of CRP in serum. The finding supports the proposed hypothesis [22] that 
the early kinetics of CRP in blood may constitute an additional tool to predict the clinical outcome 
of CSF infection. In a compliance with this hypothesis is also the finding that the highest level of 
this protein was detected in the piglets from group C8 that were most severely affected by the 
challenge infection.  
In conclusion, our results suggest that the two studied vaccines (C-strain and CP7_E2alf) exploited 
different mechanisms of the immune system. C-strain vaccination seems to activate predominantly 
the cellular immunity that probably was transferred to the offspring and might be the reason for the 
reduced mortality in the mock-vaccinated control piglets. Oppositely, the predominant elevation of 
IgG1 isotype specific antibodies following vaccination with CP7_E2alf indicates activation mainly 
of the humoral part of the acquired immunity. The detected attenuation of the CRP secretion by 
CP7_E2alf vaccine and the maternal immunity confirmed the possibility to utilize this protein as a 
tool for early prediction of CSF infection outcome. 
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Fig.1. (a) Analysis of isotype specific maternal IgG1 and IgG2 antibodies kinetics tested by ELISA in piglets obtained 
from sows vaccinated with CSFV C-strain vaccine, each symbol  for the piglets represents the mean ± SE (not equal 
number of samples were tested at each time point ) and for the sows ±SD. (b) The IgG1/IgG2 ratio, each symbol for the 
piglets represent the mean ± SE and for the sows ±SD. There was a signifficant difference of p<0.0001between IgG1 
and IGg2 at each time point tested.   
   
 
Fig.2. Analysis of IgG1 and IgG2 towards CSFV of piglets following CSFV challenge. Vaccinated piglets are shown in 
solid symbols and mock vaccinated in grey  symbols.  Serum samples were analysed for CSFV-specific IgG1(a) or 
CSFV-specific IgG2 (b) . The IgG1/IgG2 ration post challenge (c) is based on the results from Fig 2a and 2b. Each 
symbol represents the mean ± SD. The significant differences between the CRP level in the vaccinated and mock-
vaccianted control groups were indicated with *p<0.01. 
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Fig. 3. Analysis of the secreted IFN-γ in serum of piglets group V5, C5 and C8; no IFN-γ was detected in the V8 group. 
Each symbol represents the mean +SD. 
 
Fig.4. Kinetics of C-reactive protein (CRP) concentration in serum of mock-vaccinated (grey symbol) or  CP7_E2alf 
vaccinated (black symbol) piglets following CSFV challenge. Each symbol represents the mean ± SD. The significant 
differences between the CRP level in the vaccinated and mock-vaccianted control groups were indicated with 
***p<0.0001. 
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CHAPTER 3.	
Discussion,	Conclusion	and	Future	Perspectives	
 
The studies presented in this thesis focus on the efficacy of a new marker vaccine candidate 
“CP7_E2alf” in presence of MDA. This vaccine is the first live DIVA vaccine, and its potential for 
vaccination in naïve animals has been evaluated by other groups previously. At present, the live C-
strain vaccine is used widely in both domestic pigs and wild boar to prevent CSF. The “CP7_E2alf” 
will replace the C-strain. Therefore, the efficacy and the DIVA diagnostic potential of “CP7_E2alf” 
were investigated in piglets from C-strain vaccinated mothers. Additionally, immune modulation in 
these pigs and their mothers was evaluated. A small pilot study that analyzed the onset of humoral 
immune response in pigs vaccinated intramuscularly with one dose of C-strain vaccine was 
conducted at the beginning of the project.   
The first manuscript described the clinical evaluation of “CP7_E2alf” efficacy in vaccinated at 5 or 
8 weeks of age piglets and in their mock-vaccinated controls. The piglets were obtained from sows 
vaccinated intramuscularly at 4 weeks before farrowing with one dose of live attenuated C-strain 
vaccine. The challenge virus used for the infection of the vaccinated piglets was the highly virulent 
strain “Koslov”. Post challenge, the protocol proposed by Mittelholzer et al., 2000 was followed in 
order to evaluate the progress of the infection. The results revealed that “CP7_E2alf” provided 
clinical protection as no severe clinical signs or mortality was observed in the vaccinated piglets. 
The DIVA potential of the new vaccine and the possibility for transfer of C-strain maternal derived 
Erns and E2 specific antibody was evaluated in the same piglets by Erns and E2 specific antibody 
ELISA test. MDA kinetics was assessed as well. The results presented in the second manuscript 
demonstrated that “CP7_E2alf” could be implemented as a DIVA vaccine in population previously 
vaccinated with the modified live attenuated C-strain vaccine. Maternal Erns specific antibodies 
were transferred to some of the piglets and were detected up to four weeks of age. Immune 
modulation after vaccination of the sows and the piglets with regard to IgG1 and IgG2 isotype 
specific antibodies was evaluated. Additionally, the related to IgG1 and IgG2 isotype specific 
antibodies cytokines were analyzed in the piglets post challenge. The results suggest that C-strain 
and “CP7_E2alf” exploit different mechanisms of the immune system in providing protection.  
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The mortality rate in the mock-vaccinated piglets was significantly reduced compared to previous 
studies (Mittelholzer et al., 2000; Lohse et al., 2011) and there was a clear difference between the 
piglets challenged at 7 or at 10 weeks of age. We first suggested that the MDAs level at the time of 
challenge might be an explanation for the significant attenuation of the infectious virus. 
Surprisingly, when the serum samples were analyzed with neutralization test the results showed no 
difference in the neutralization titer obtained from the piglets that survived and these that 
succumbed to the infection. Furthermore, the neutralization titer was lower than previously claimed 
to be necessary for protection (Terpstra and Wensvoort, 1987). Thus, the attenuation of the 
infectious virus probably was due to a complex of virus-host factors. The neutralization of “Koslov” 
strain by low titers of MDAs might be explained with the close phylogeny as both “Koslov” and the 
vaccine C-strain belong to genotype 1 (Bartak and Greiser-Wilke, 2000). Additionally, the 
involvement of other than humoral part of the immune system host factors could play a significant 
role in the removal of the virus. Transfer of functional protective colostral antigen-specific T-cell 
from vaccinated sows to their piglets was previously reported (Bandrick et al., 2008). The third 
manuscript demonstrated detection of significantly higher concentration of IgG2 compared to IgG1 
isotype specific antibodies in the sows what suggests predominant activation of the cellular immune 
response post C-strain vaccination. Thus, a transfer of protective cellular mediated immunity to 
their piglets is very likely.  
CSF vaccine virus is known to target mainly the tonsils and the challenge virus of this study showed 
the same pattern. Interestingly, some of the mock vaccinated piglets challenged at 7 weeks of age 
had the virus in the tonsils, but did not show clinical signs. A possible development of a chronic 
infection in these piglets due to the MDA that prevented morbidity could be an explanation. In a 
case of outbreak, these piglets are a potential risk for long undetected transmission of CSFV.  
We can discuss the relevancy of the used protocol and CS (Mittelholzer et al., 2000) in regard to the 
challenge virus. The mock-vaccinated animals that succumbed to the infection had low CS and their 
temperature rarely exceeded 41.0◦C, which is expected for infections with highly virulent strains 
CSFV. It is not clear whether the reason is a possible attenuation of the infectious virus by the 
maternal immunity or an acute course of the disease that cause mortality before onset of clinical 
signs. Mortality with low CSs after challenge with another highly virulent strain that belongs also to 
genotype 1 was reported previously (Tarradas et al., 2011). Thus, more relevant for these CSFV 
strains might be the proposed by Floegel-Niesmann et al. 2003 modified CS schema that includes 
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some other parameters such as: case fatality, pathological scores, leukocyte count and homologue 
CSF antibody titer. In agreement with this schema, our observations revealed clear correlation 
between white blood cells count and the virulence of the CSFV. Furthermore, some additional 
hematological and immunological parameters could be included when CSF virulence is evaluated in 
vivo. Mark reduction of the platelets counts were detected in all piglets that succumbed to the 
challenge infection. Based on the detected correlation of CRP concentration in blood and the 
outcome of the infection, early kinetics of CRP could be another supplementary parameter.  
Despite the variable disease course in the control-mock vaccinated animals no interference of 
maternal immunity with DIVA concept in these animals was observed and seroconversion to Erns 
specific antibodies was detected in all piglets from day 10 post challenge. The very early 
seroconversion at day 3 post challenge of one vaccinated piglet indicated a possible cross reactivity 
with the vaccine BVDV Erns specific antibodies. This possibility is supported by the statistically 
significant difference between these results and the results obtained by the corresponding control 
mock-vaccinated group.  
The transfer of maternal immunity seemed to show discrepancy between the results obtained from 
the sows by NLPA assay and Erns ELISA test. This low sensitivity of the Erns ELISA test with serum 
samples from C-strain vaccinated pigs was reported previously and the lack of vaccine viral 
replication is likely the explanation. However, when analyzing the Erns specific antibodies that the 
piglets had received from the sows, they had a higher inhibition percent than their mothers.  
Future	Perspectives	
Results of the studies presented here suggest a number of possibilities for future research as 
outlined below.  
The efficacy of “CP7_E2alf” vaccine in face of maternal immunity in domestic piglets 
intramuscularly vaccinated was evaluated. As this vaccine is intended also for baits vaccination of 
wild boar future studies could be performed in this target species. The persistence of MDA in the 
piglets depends on the level of antibodies in the individual sow and the amount of colostrums they 
obtain from their mothers. Wild boar give birth to fewer piglets than domestic sows, thus with fewer 
piglets to feed it is probable that the outcome of vaccination study in wild boar will be different. 
Oral immunization activates different parts of the immune system, what could additionally alter the 
successful vaccination observed in our study.  
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The protective ability of the MDA may differ with the challenge virus used. A future study could 
test as well the protection ability of MDA from C-strain in piglets infected with highly virulent 
strains of genotype 2 or 3. CSFVs that belong to genotype 2 are responsible for the latest outbreaks 
of CSFV in Europe and strains from genotype 3 are wildly spread in Asia, where routine 
prophylactic vaccination with C-strain is performed.   
Half life of MDA depends on the time point of sow’s vaccination and on the infection pressure in 
the population, thus different vaccination schedules of the sows could be performed to mirror field 
situation with piglets having variable neutralization antibodies titers.  
Addition of a vaccinated not challenged group could be valuable in providing conformation of the 
DIVA potential of “CP7_E2alf”. In order to evaluate the marker vaccine’s efficacy in case of 
emergency the challenge infection could be performed one week after vaccination. This new marker 
is going to be used in a case of outbreak and its ability to prevent transmission of the infectious 
virus is of significant importance. Our results showed that the vaccine is able to reduce the 
challenge viral genome, but a contact not infected group is needed to support this observation. 
Longer post challenge period could be very beneficial. At the end of the animal experiment, the 
survived infection mock-vaccinated piglets did not show severe clinical signs, fever or their white 
blood cell counts come to physiological levels. Thus, observation of these piglets for more than two 
weeks will give us the possibility to confirm their true recovery.  
It will be very interesting to study the efficacy of CP7_E2alf in piglets younger than 5 weeks. 
According to the literature, when younger piglets were vaccinated with C-strain clear interference 
of the MDA with the vaccine efficacy was observed. However, as it seems that the two vaccines 
exploit different mechanisms of the immune system, the outcome of CP7_E2alf in younger piglets 
could be quite different.   
The potential role of the cellular part of the immune system in the protection against CSF needs 
further evaluation. Transfer of activated maternal cellular and innate immunity components with 
colostrums and milk will give us a possibility to better understand the factors involved in early life 
vaccinology. An animal study conducted at CVI Netherlands tested the efficacy of “CP7E2alf” in 
piglets from “CP7E2alf” vaccinated mothers and oppositely to our findings all of the piglets 
succumbed to the challenge infection (personal correspondence, CSFV_goDIVA). Thus, a future 
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collaboration between the two research groups to study the possible reason for the obtained results 
could be very beneficial.  
Further investigation of immune modulation after C-strain and “CP7_E2alf” vaccination could be 
also of interest. This research should include additional Th1 and Th2 cytokines. We tested IL4 and 
IFN-γ concentration in serum by ELISA test and found only a few IFN-γ and no IL4, but a recently 
published study (Renson et al., 2012) assessed the gene expression of these cytokines in blood cells 
by real time RT-PCR.   
Conclusions  
The studies performed in this thesis leads to several conclusions. 
Studies within the CSFV_goDIVA project has shown that “CP7E2alf” is a promising marker 
vaccine that can replace the current modified live attenuated C-strain vaccine. Previous studies have 
been conducted in naïve piglets. Here it is shown that the successful vaccination with the new 
marker vaccine was not affected by the C-strain MDA as all vaccinated piglets were protected 
against morbidity, mortality and pathological lesions.  
“CP7_E2alf” can be implemented as a marker vaccine in populations previously vaccinated with C-
strain when the piglets have reached 5 weeks of age, as no interference of the MDA and the vaccine 
with the DIVA potential at this age was observed. The MDA concentrations at 7 and 10 weeks of 
age were insufficient to neutralize the challenge virus and to prevent seroconversion to Erns specific 
antibodies. 
Pig producers are in need of a vaccine against CSFV with good efficacy and DIVA ability. The 
“CP7_E2alf” seems to have all these potentials and with the ability to overcome maternal immunity 
it looks even more promising. The vaccine is primarily intended for emergency use and further 
studies are still needed before the vaccine can be used also in countries with large pig export. The 
collaboration between a large group of research partners and a commercial partner in this EU 
project has been a great leap forward.  
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